|
G |
Alox15 |
arachidonate 15-lipoxygenase |
multiple interactions increases abundance increases chemical synthesis |
EXP ISO |
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; [Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] ALOX15 protein results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid ALOX15 protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:18984061 PMID:21193584 PMID:23872364 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
[benoxaprofen results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [Masoprocol results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [RS 43179 results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [tenidap results in decreased activity of ALOX5 protein] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:2849922 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
App |
amyloid beta precursor protein |
increases secretion multiple interactions |
ISO |
APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid CNB 001 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; Dronabinol inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid]; L 685458 inhibits the reaction [APP protein modified form results in increased secretion of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Egf |
epidermal growth factor |
multiple interactions increases chemical synthesis |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein] EGF protein results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15613483 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases activity |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of EPHX2 protein |
CTD |
PMID:25600587 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Hgf |
hepatocyte growth factor |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] |
CTD |
PMID:15613483 |
|
NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409
|
|
G |
Il1b |
interleukin 1 beta |
increases secretion multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of IL1B protein IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] |
CTD |
PMID:23355332 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Kcna5 |
potassium voltage-gated channel subfamily A member 5 |
multiple interactions affects activity |
EXP |
[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA; [[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 protein; cinnamyl-3,4-dihydroxycyanocinnamate inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA]; Masoprocol inhibits the reaction [[[Oxygen deficiency results in increased activity of ALOX15 protein] which results in increased chemical synthesis of 15-hydroxy-5,8,11,13-eicosatetraenoic acid] which results in decreased expression of KCNA5 mRNA] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNA5 protein |
CTD |
PMID:18984061 |
|
NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697
|
|
G |
Kcnb1 |
potassium voltage-gated channel subfamily B member 1 |
affects activity |
EXP |
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNB1 protein |
CTD |
PMID:18984061 |
|
NCBI chr 3:155,820,255...155,913,383
Ensembl chr 3:155,822,963...155,916,194
|
|
G |
Kcnc4 |
potassium voltage-gated channel subfamily C member 4 |
affects activity |
EXP |
15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the activity of KCNC4 protein |
CTD |
PMID:18984061 |
|
NCBI chr 2:195,063,967...195,100,244
Ensembl chr 2:195,071,769...195,099,233
|
|
G |
Krt1 |
keratin 1 |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Calcium results in increased expression of KRT1 mRNA] |
CTD |
PMID:12069687 |
|
NCBI chr 7:132,976,618...132,981,844
Ensembl chr 7:132,976,620...132,981,844
|
|
G |
Lyz2 |
lysozyme 2 |
increases secretion multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein [parthenolide co-treated with artemisinin co-treated with Quercetin] inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; parthenolide inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; SB 203580 inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] |
CTD |
PMID:23355332 |
|
NCBI chr 7:52,906,810...52,912,154
Ensembl chr 7:52,906,811...52,912,106
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:25600587 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:25600587 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
increases activity affects localization multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of NFKB1 protein 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of NFKB1 protein] |
CTD |
PMID:23355332 PMID:25600587 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein; Quercetin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased phosphorylation of and results in increased degradation of NFKBIA protein] |
CTD |
PMID:15451026 PMID:23355332 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nppa |
natriuretic peptide A |
increases expression |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPA mRNA |
CTD |
PMID:25600587 |
|
NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351
|
|
G |
Nppb |
natriuretic peptide B |
increases expression |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased expression of NPPB mRNA |
CTD |
PMID:25600587 |
|
NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
multiple interactions |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid binds to and results in increased activity of PPARD protein |
CTD |
PMID:12069687 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Prkca |
protein kinase C, alpha |
multiple interactions increases activity affects localization |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [EGF protein affects the localization of PRKCA protein]; 15-hydroxy-5,8,11,13-eicosatetraenoic acid promotes the reaction [HGF protein affects the localization of PRKCA protein] calphostin C inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of PRKCA protein] 15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of PRKCA protein |
CTD |
PMID:15451026 PMID:15613483 |
|
NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases activity multiple interactions affects localization |
ISO |
15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased activity of RELA protein artemisinin inhibits the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid affects the localization of RELA protein] |
CTD |
PMID:23355332 PMID:25600587 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
IL1B protein affects the reaction [TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]]; TNF protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]; TNF protein affects the reaction [IL1B protein affects the reaction [15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of LYZ protein]] 15-hydroxy-5,8,11,13-eicosatetraenoic acid results in increased secretion of TNF protein |
CTD |
PMID:23355332 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 15-hydroxy-5,8,11,13-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Lipg |
lipase G, endothelial type |
increases hydrolysis |
ISO |
LIPG protein results in increased hydrolysis of 1-O-hexadecyl-2-arachidonyl-sn-glycero-3-phosphocholine |
CTD |
PMID:15953354 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
increases metabolic processing |
ISO |
DAGLA protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases metabolic processing |
ISO |
DAGLB protein results in increased metabolism of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:18657971 |
|
NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Dgke |
diacylglycerol kinase epsilon |
increases phosphorylation |
ISO |
DGKE protein results in increased phosphorylation of 1-stearoyl-2-arachidonoylglycerol |
CTD |
PMID:17455907 |
|
NCBI chr10:73,853,030...73,877,334
Ensembl chr10:73,855,583...73,877,100
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
increases expression |
ISO |
1-stearoyl-2-arachidonoylglycerol results in increased expression of PPARGC1A mRNA |
CTD |
PMID:23056435 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
1-stearoyl-2-arachidonoylglycerol inhibits the reaction [TGFB1 protein results in increased expression of COL1A1 mRNA] |
CTD |
PMID:27936102 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Trpm6 |
transient receptor potential cation channel, subfamily M, member 6 |
multiple interactions |
ISO |
TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Barium]; TRPM6 protein affects the reaction [1-stearoyl-2-arachidonoylglycerol results in increased transport of Calcium] |
CTD |
PMID:11988098 |
|
NCBI chr 1:216,136,407...216,320,523
Ensembl chr 1:216,170,038...216,320,520
|
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
increases response to substance |
ISO |
GPX1 protein results in increased susceptibility to 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases chemical synthesis |
ISO |
GPX4 protein results in increased chemical synthesis of 12-HPETE |
CTD |
PMID:11115402 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 12-HPETE inhibits the reaction [Sodium Salicylate results in decreased activity of PTGS2 protein] |
CTD |
PMID:12538810 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
|
G |
Ace |
angiotensin I converting enzyme |
decreases activity |
EXP |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased activity of ACE protein |
CTD |
PMID:27428043 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ace2 |
angiotensin converting enzyme 2 |
multiple interactions |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog promotes the reaction [REN2 protein results in increased expression of ACE2 protein] |
CTD |
PMID:27428043 |
|
NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977
|
|
G |
Agt |
angiotensinogen |
decreases expression multiple interactions increases cleavage |
EXP ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid analog results in decreased expression of AGT protein modified form [14,15-epoxy-5,8,11-eicosatrienoic acid analog results in increased cleavage of AGT protein modified form] which results in increased abundance of angiotensin I (1-7) 14,15-epoxy-5,8,11-eicosatrienoic acid analog inhibits the reaction [REN2 protein results in increased expression of AGT protein modified form] |
CTD |
PMID:27428043 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of AKT1 protein |
CTD |
PMID:16286479 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases chemical synthesis |
ISO |
CYP2C8 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:12675279 |
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
multiple interactions increases abundance |
ISO |
[Arsenites results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid; [Mercuric Chloride results in increased expression of and results in increased activity of EPHX2 protein] which results in decreased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid EPHX2 gene mutant form results in increased abundance of 14,15-epoxy-5,8,11-eicosatrienoic acid |
CTD |
PMID:19896470 PMID:22680237 PMID:24472606 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased expression of FGF2 protein |
CTD |
PMID:16286479 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19464254 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19464254 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
increases phosphorylation |
ISO |
14,15-epoxy-5,8,11-eicosatrienoic acid results in increased phosphorylation of RPS6KB1 protein |
CTD |
PMID:16286479 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
decreases secretion multiple interactions |
ISO |
TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid 12-(3-adamantan-1-ylureido)dodecanoic acid inhibits the reaction [TGFB1 protein results in decreased secretion of 14,15-epoxy-5,8,11-eicosatrienoic acid] |
CTD |
PMID:28694203 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in increased expression of HMOX1 protein |
CTD |
PMID:25450232 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Ikbkb |
inhibitor of nuclear factor kappa B kinase subunit beta |
multiple interactions decreases activity |
ISO |
[15-keto-5,8,11,13-eicosatetraenoic acid results in decreased activity of IKBKB protein] which results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:25450232 |
|
NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[15-keto-5,8,11,13-eicosatetraenoic acid results in decreased activity of IKBKB protein] which results in decreased phosphorylation of NFKBIA protein |
CTD |
PMID:25450232 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in increased expression of NQO1 protein |
CTD |
PMID:25450232 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO |
15-keto-5,8,11,13-eicosatetraenoic acid results in decreased expression of TNF mRNA 15-keto-5,8,11,13-eicosatetraenoic acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA] |
CTD |
PMID:25450232 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing |
EXP |
CYP2E1 protein affects the metabolism of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15205388 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 19-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
increases hydrolysis |
ISO |
ABHD12 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr 3:139,659,315...139,719,529
Ensembl chr 3:139,659,317...139,719,564
|
|
G |
Abhd6 |
abhydrolase domain containing 6, acylglycerol lipase |
increases hydrolysis |
ISO |
ABHD6 protein results in increased hydrolysis of glyceryl 2-arachidonate |
CTD |
PMID:18096503 |
|
NCBI chr15:16,859,740...16,907,094
Ensembl chr15:16,859,738...16,906,985
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
EXP |
glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of ACTA2 mRNA] |
CTD |
PMID:21863215 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions |
ISO |
[[APOE protein affects the susceptibility to [Cholesterol, Dietary co-treated with Dietary Fats]] which affects the susceptibility to JZL 184] which affects the abundance of glyceryl 2-arachidonate |
CTD |
PMID:29813086 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of ATF4 mRNA iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of ATF4 mRNA] |
CTD |
PMID:32357311 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of BTG2 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr13:45,531,881...45,535,642
Ensembl chr13:45,531,925...45,535,628
|
|
G |
Casp3 |
caspase 3 |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of CASP3 mRNA |
CTD |
PMID:38462211 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCL2 protein |
CTD |
PMID:15115777 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccr1 |
C-C motif chemokine receptor 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CCR1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:123,556,286...123,561,841
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of CD36 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Ces1d |
carboxylesterase 1D |
increases hydrolysis multiple interactions |
ISO |
CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
increases hydrolysis multiple interactions |
ISO |
CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate [CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions increases expression |
ISO EXP |
[CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of glyceryl 2-arachidonate; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate results in increased expression of CNR1 mRNA [GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA]; glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] Acetaldehyde promotes the reaction [glyceryl 2-arachidonate results in increased expression of CNR1 mRNA]; Nitroglycerin affects the reaction [glyceryl 2-arachidonate affects the activity of CNR1 protein] |
CTD |
PMID:12657697 PMID:15899896 PMID:16775503 PMID:21863215 PMID:23894352 PMID:26209559 PMID:28095641 PMID:31024316 PMID:36858108 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions affects response to substance |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; [SR 144528 binds to and results in increased activity of CNR2 protein] inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased expression of CXCL8 protein]; CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]; glyceryl 2-arachidonate binds to and results in increased activity of CNR2 protein; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB1 protein]; glyceryl 2-arachidonate promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; Pertussis Toxin inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]]; SR 144528 inhibits the reaction [CNR2 protein affects the reaction [glyceryl 2-arachidonate results in increased transport of Calcium]] CNR2 gene SNP affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:10617657 PMID:15115777 PMID:20124950 PMID:27194477 PMID:30102254 PMID:31024316 More...
|
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb3l3 |
cAMP responsive element binding protein 3-like 3 |
multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 7:8,622,614...8,631,053
Ensembl chr 7:8,622,614...8,631,048
|
|
G |
Crh |
corticotropin releasing hormone |
increases abundance |
ISO |
CRH protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp27a1 |
cytochrome P450, family 27, subfamily a, polypeptide 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
multiple interactions increases expression |
ISO |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA]; glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Cyp7b1 |
cytochrome P450 family 7 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7B1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 2:100,502,791...100,669,713
Ensembl chr 2:100,502,791...100,669,698
|
|
G |
Cyp8b1 |
cytochrome P450 family 8 subfamily B member 1 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP8B1 mRNA] |
CTD |
PMID:23894352 PMID:28095641 |
|
NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
multiple interactions |
ISO |
1-((fluoro(methyl)phosphoryl)oxy)-3-isopropoxypropan-2-yl oleate inhibits the reaction [DAGLA protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA; glyceryl 2-arachidonate results in increased expression of DDIT3 protein iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 mRNA]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased expression of DDIT3 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Egf |
epidermal growth factor |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of EGF mRNA; glyceryl 2-arachidonate affects the expression of EGF protein |
CTD |
PMID:38462211 |
|
NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
multiple interactions increases phosphorylation |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein]; iodopravadoline inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:32357311 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases abundance |
ISO |
ESRRG protein results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:31912162 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
affects abundance multiple interactions |
ISO |
FABP1 protein affects the abundance of glyceryl 2-arachidonate FABP1 protein affects the reaction [Dronabinol results in increased abundance of glyceryl 2-arachidonate]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of FGF1 mRNA |
CTD |
PMID:38462211 |
|
NCBI chr18:30,686,555...30,772,667
Ensembl chr18:30,686,581...30,772,357
|
|
G |
Fmr1 |
fragile X messenger ribonucleoprotein 1 |
multiple interactions |
ISO |
[FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate |
CTD |
PMID:20393458 |
|
NCBI chr X:147,240,239...147,278,057
Ensembl chr X:147,240,301...147,278,050
|
|
G |
Fyn |
FYN proto-oncogene, Src family tyrosine kinase |
multiple interactions |
EXP |
FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 |
|
NCBI chr20:42,767,733...42,960,903
Ensembl chr20:42,766,369...42,959,911
|
|
G |
Gdnf |
glial cell derived neurotrophic factor |
affects expression |
ISO |
glyceryl 2-arachidonate affects the expression of GDNF mRNA; glyceryl 2-arachidonate affects the expression of GDNF protein |
CTD |
PMID:38462211 |
|
NCBI chr 2:56,894,022...56,919,935
Ensembl chr 2:56,895,010...56,917,209
|
|
G |
Grk2 |
G protein-coupled receptor kinase 2 |
multiple interactions |
ISO |
[GRK2 protein co-treated with glyceryl 2-arachidonate] affects the reaction [CNR1 protein affects the localization of ARRB2 protein]; [GRK2 protein co-treated with glyceryl 2-arachidonate] promotes the reaction [CNR2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [glyceryl 2-arachidonate affects the reaction [CNR1 protein affects the localization of ARRB1 protein]] |
CTD |
PMID:31024316 |
|
NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases chemical synthesis multiple interactions |
ISO |
HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate 1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea inhibits the reaction [HCRT protein modified form results in increased chemical synthesis of glyceryl 2-arachidonate] |
CTD |
PMID:27071101 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of HSPA5 mRNA |
CTD |
PMID:32357311 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of ICAM1 mRNA |
CTD |
PMID:29813086 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il1b |
interleukin 1 beta |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL1B mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
multiple interactions |
ISO |
glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]; T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased secretion of IL2 protein]] |
CTD |
PMID:21511917 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Il6 |
interleukin 6 |
decreases expression multiple interactions |
ISO |
glyceryl 2-arachidonate results in decreased expression of IL6 mRNA glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:16364651 PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]; N-(3-methoxyphenyl)-4-chlorocinnamanilide inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [INS1 protein results in increased uptake of Deoxyglucose]] |
CTD |
PMID:31408376 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
multiple interactions |
ISO |
INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP27A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate promotes the reaction [CREB3L3 protein binds to CYP7A1 promoter]]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CREB3L3 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP27A1 mRNA]; INS protein inhibits the reaction [glyceryl 2-arachidonate results in increased expression of CYP7A1 mRNA] |
CTD |
PMID:23894352 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
[Dietary Fats co-treated with LEP protein] results in increased chemical synthesis of glyceryl 2-arachidonate |
CTD |
PMID:27071101 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK1 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions decreases phosphorylation |
ISO EXP |
CNR1 gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; FYN gene mutant form inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in decreased phosphorylation of MAPK3 protein]; Rimonabant inhibits the reaction [glyceryl 2-arachidonate results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:31917333 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgll |
monoglyceride lipase |
multiple interactions affects abundance increases degradation increases abundance increases hydrolysis |
EXP ISO |
[Chlorpyrifos results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; JZL 184 inhibits the reaction [MGLL protein results in increased hydrolysis of glyceryl 2-arachidonate] MGLL protein affects the abundance of glyceryl 2-arachidonate MGLL protein results in increased degradation of glyceryl 2-arachidonate [FMR1 gene mutant form results in increased activity of MGLL] which results in increased degradation of glyceryl 2-arachidonate; [JZL 184 results in decreased activity of MGLL protein] which results in increased abundance of glyceryl 2-arachidonate; [MJN110 results in decreased activity of MGLL protein] which results in decreased hydrolysis of and results in increased abundance of glyceryl 2-arachidonate MGLL gene mutant form results in increased abundance of glyceryl 2-arachidonate |
CTD |
PMID:18096503 PMID:20393458 PMID:21507991 PMID:23761300 PMID:25030704 PMID:26209559 PMID:26642910 PMID:26791602 PMID:30301768 More...
|
|
NCBI chr 4:121,192,186...121,294,187
Ensembl chr 4:121,192,195...121,294,179
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions |
ISO |
glyceryl 2-arachidonate inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased activity of MPO protein]] |
CTD |
PMID:30611738 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
GSK2656157 inhibits the reaction [glyceryl 2-arachidonate results in increased cleavage of PARP1 protein] |
CTD |
PMID:29441458 PMID:32357311 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
affects localization multiple interactions |
EXP |
glyceryl 2-arachidonate affects the localization of PPARA protein [palmidrol co-treated with glyceryl 2-arachidonate] affects the localization of PPARA protein; [palmidrol co-treated with glyceryl 2-arachidonate] affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein]; glyceryl 2-arachidonate affects the reaction [lipopolysaccharide, E. coli O26-B6 affects the localization of PPARA protein] |
CTD |
PMID:31787870 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
affects binding multiple interactions increases expression |
ISO |
glyceryl 2-arachidonate metabolite binds to PPARG protein glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in decreased expression of PPARG protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] T 0070907 inhibits the reaction [glyceryl 2-arachidonate metabolite results in increased expression of PPARG mRNA] |
CTD |
PMID:21511917 PMID:26209559 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
EXP |
[Indomethacin results in decreased expression of PTGS1] which results in increased activity of glyceryl 2-arachidonate |
CTD |
PMID:17245358 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases metabolic processing multiple interactions |
ISO |
PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate 2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; CNR1 protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]]; rimonabant inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased expression of PTGS2 protein]] glyceryl 2-arachidonate inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Calcium Ionophores] results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of glyceryl 2-arachidonate] |
CTD |
PMID:18297109 PMID:21511917 PMID:26209559 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
2-chloro-5-nitrobenzanilide inhibits the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]]; glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]; PPARG protein affects the reaction [glyceryl 2-arachidonate inhibits the reaction [Sulfur Dioxide results in increased phosphorylation of RELA protein]] |
CTD |
PMID:26209559 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Tnf |
tumor necrosis factor |
decreases expression multiple interactions |
ISO EXP |
glyceryl 2-arachidonate results in decreased expression of TNF mRNA glyceryl 2-arachidonate inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein]; glyceryl 2-arachidonate inhibits the reaction [amyloid beta-protein (25-35) results in increased expression of TNF protein] glyceryl 2-arachidonate inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] |
CTD |
PMID:12509806 PMID:16364651 PMID:30611738 PMID:30769029 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions affects response to substance |
EXP ISO |
glyceryl 2-arachidonate binds to and results in increased activity of TRPV1 protein TRPV1 protein affects the susceptibility to glyceryl 2-arachidonate |
CTD |
PMID:18550765 PMID:21949157 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Yy1 |
YY1 transcription factor |
increases expression |
ISO |
glyceryl 2-arachidonate results in increased expression of YY1 mRNA |
CTD |
PMID:28095641 |
|
NCBI chr 6:127,706,739...127,736,499
Ensembl chr 6:127,707,596...127,732,747
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression multiple interactions |
ISO |
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of ACTA2 protein] |
CTD |
PMID:36368619 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Clock |
clock circadian regulator |
affects abundance |
ISO |
CLOCK protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:22440902 |
|
NCBI chr14:31,908,542...31,992,673
Ensembl chr14:31,908,566...31,990,400
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
multiple interactions increases expression |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of COL1A1 protein |
CTD |
PMID:36368619 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Cyp4a1 |
cytochrome P450, family 4, subfamily a, polypeptide 1 |
multiple interactions increases chemical synthesis |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid affects the reaction [CYP4A1 protein affects the susceptibility to Phenylephrine]; 20-hydroxy-5,8,11,14-eicosatetraenoic acid inhibits the reaction [DDMS inhibits the reaction [CYP4A1 protein results in increased susceptibility to Phenylephrine]] CYP4A1 protein results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:11124159 PMID:12388396 |
|
NCBI chr 5:129,123,323...129,137,464
Ensembl chr 5:129,123,336...129,137,464
|
|
G |
Cyp4a2 |
cytochrome P450, family 4, subfamily a, polypeptide 2 |
increases expression |
EXP |
20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of CYP4A2 mRNA |
CTD |
PMID:22442195 |
|
NCBI chr 5:128,922,355...128,934,188
Ensembl chr 5:128,923,615...128,934,165
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases chemical synthesis |
ISO |
CYP4F3 protein alternative form results in increased chemical synthesis of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
G |
Nfatc4 |
nuclear factor of activated T-cells 4 |
multiple interactions increases localization |
ISO EXP |
Cyclosporine inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein]; Tacrolimus inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased localization of NFATC4 protein] |
CTD |
PMID:16055480 |
|
NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions increases abundance |
EXP |
HET0016 inhibits the reaction [POMC protein affects the abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid] POMC protein results in increased abundance of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:18067589 PMID:19458537 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Smad3 |
SMAD family member 3 |
multiple interactions increases phosphorylation |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased phosphorylation of SMAD3 protein] |
CTD |
PMID:36368619 |
|
NCBI chr 8:64,126,829...64,236,960
Ensembl chr 8:64,110,039...64,236,960
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions increases expression |
ISO |
20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-5(Z),14(Z)-dienoic acid promotes the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA]; 20-hydroxyeicosa-6(Z),15(Z)-dienoic acid inhibits the reaction [20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein] 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 mRNA; 20-hydroxy-5,8,11,14-eicosatetraenoic acid results in increased expression of TGFB1 protein |
CTD |
PMID:36368619 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of 20-hydroxy-5,8,11,14-eicosatetraenoic acid |
CTD |
PMID:15231852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 5,6-epoxy-8,11,14-eicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases abundance |
ISO |
EPHX2 gene mutant form results in increased abundance of 5,6-epoxy-8,11,14-eicosatrienoic acid |
CTD |
PMID:19896470 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases secretion |
ISO |
5-oxo-6,8,11,14-eicosatetraenoic acid results in increased secretion of CSF2 protein |
CTD |
PMID:15136573 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases chemical synthesis |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 8,9-epoxyeicosatrienoic acid] |
CTD |
PMID:12675279 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
affects hydrolysis |
ISO |
EPHX1 protein affects the hydrolysis of 8,9-epoxyeicosatrienoic acid |
CTD |
PMID:28975360 |
|
NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases abundance |
ISO |
EPHX2 gene mutant form results in increased abundance of 8,9-epoxyeicosatrienoic acid |
CTD |
PMID:19896470 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [AGT protein results in increased abundance of Epoprostenol] |
CTD |
PMID:14613874 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:18938131 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [[ENPP2 protein co-treated with Capsaicin] results in increased abundance of lysophosphatidic acid] |
CTD |
PMID:19014389 |
|
NCBI chr 7:86,202,345...86,325,050
Ensembl chr 7:86,202,350...86,324,827
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NAD inhibits the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased secretion of IL1B protein]] |
CTD |
PMID:29642561 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
EXP |
arachidonyltrifluoromethane inhibits the reaction [BL 11282 promotes the reaction [Glucose results in increased secretion of INS1 protein]] |
CTD |
PMID:17922229 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Ins2 |
insulin 2 |
increases secretion multiple interactions |
ISO |
arachidonyltrifluoromethane results in increased secretion of INS protein arachidonyltrifluoromethane inhibits the reaction [Glucose results in increased secretion of INS protein] |
CTD |
PMID:17192482 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:15231676 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK1 protein]; arachidonyltrifluoromethane inhibits the reaction [NRG1 protein alternative form results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:15231676 |
|
NCBI chr16:59,250,658...60,304,519
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PLA2G4A protein] arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PLA2G4A mRNA] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of PTGS2 protein]; arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]] |
CTD |
PMID:18938131 PMID:19063610 PMID:19162293 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
S100a11 |
S100 calcium binding protein A11 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Cisplatin]; arachidonyltrifluoromethane inhibits the reaction [S100A11 mutant form results in increased susceptibility to Oxaliplatin] |
CTD |
PMID:25940438 |
|
NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [TNF protein results in increased expression of SOD2] |
CTD |
PMID:11264281 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
arachidonyltrifluoromethane inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA] arachidonyltrifluoromethane promotes the reaction [Nifedipine inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VEGFA mRNA]] |
CTD |
PMID:19063610 PMID:19162293 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases export |
ISO |
ABCB1 protein results in increased export of anandamide |
CTD |
PMID:30102254 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions decreases expression |
ISO |
8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA]; anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ABCG2 mRNA]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]]; iodopravadoline inhibits the reaction [anandamide results in decreased expression of ABCG2 mRNA] anandamide results in decreased expression of ABCG2 mRNA; anandamide results in decreased expression of ABCG2 protein |
CTD |
PMID:30610963 PMID:34756920 |
|
NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409
|
|
G |
Acox1 |
acyl-CoA oxidase 1 |
multiple interactions |
ISO |
anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of ACOX1 mRNA] |
CTD |
PMID:34756920 |
|
NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232
|
|
G |
Agpat2 |
1-acylglycerol-3-phosphate O-acyltransferase 2 |
multiple interactions |
ISO |
anandamide affects the reaction [O,O-diethyl O-3,5,6-trichloro-2-pyridyl phosphate affects the expression of AGPAT2 mRNA] |
CTD |
PMID:34756920 |
|
NCBI chr 3:9,416,837...9,428,567
Ensembl chr 3:9,416,843...9,428,371
|
|
G |
App |
amyloid beta precursor protein |
decreases response to substance decreases metabolic processing decreases abundance |
EXP ISO |
anandamide results in decreased susceptibility to APP protein APP protein results in decreased metabolism of anandamide APP protein results in decreased abundance of anandamide |
CTD |
PMID:22233683 PMID:26976670 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein] |
CTD |
PMID:31024316 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions decreases activity |
ISO |
AM 251 inhibits the reaction [anandamide results in decreased activity of BDKRB1 protein] |
CTD |
PMID:19022239 |
|
NCBI chr 6:124,510,827...124,514,475
Ensembl chr 6:124,510,870...124,513,747
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions |
ISO |
anandamide results in increased cleavage of CASP3 protein 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased cleavage of CASP3 protein] |
CTD |
PMID:26513129 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
ISO |
anandamide results in increased expression of CD36 mRNA; anandamide results in increased expression of CD36 protein |
CTD |
PMID:17360047 |
|
NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903
|
|
G |
Cga |
glycoprotein hormones, alpha polypeptide |
decreases expression |
ISO |
anandamide results in decreased expression of CGA mRNA |
CTD |
PMID:30610963 |
|
NCBI chr 5:49,486,915...49,499,192
Ensembl chr 5:49,487,068...49,499,191
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
affects activity increases response to substance decreases expression affects binding increases activity multiple interactions |
ISO EXP |
anandamide affects the activity of CNR1 protein CNR1 protein results in increased susceptibility to anandamide anandamide results in decreased expression of CNR1 protein anandamide binds to CNR1 protein anandamide results in increased activity of CNR1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased activity of CNR1]; anandamide promotes the reaction [CNR1 protein affects the localization of ARRB2 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Pertussis Toxin inhibits the reaction [anandamide results in increased activity of CNR1]; Rimonabant inhibits the reaction [anandamide results in increased activity of CNR1] [anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased abundance of Nitric Oxide]; [CNR1 protein affects the susceptibility to Chlorpyrifos] which affects the hydrolysis of anandamide; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Rimonabant inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]]; SR 144528 inhibits the reaction [[anandamide binds to and results in increased activity of CNR1 protein] inhibits the reaction [Lipopolysaccharides results in increased transport of Nitric Oxide]] |
CTD |
PMID:10871313 PMID:11408034 PMID:11891798 PMID:12657697 PMID:14504685 PMID:15453094 PMID:17557913 PMID:19147270 PMID:29730318 PMID:31024316 PMID:31199905 PMID:36858108 More...
|
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
affects activity affects binding multiple interactions |
ISO EXP |
anandamide affects the activity of CNR2 protein anandamide binds to CNR2 protein anandamide binds to and results in increased activity of CNR2 protein; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide] |
CTD |
PMID:10617657 PMID:10688601 PMID:15453094 PMID:19147270 PMID:30102254 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
anandamide inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]; anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]; Colforsin inhibits the reaction [anandamide inhibits the reaction [CREB1 protein modified form binds to ABCG2 promoter]] anandamide results in decreased phosphorylation of CREB1 protein |
CTD |
PMID:30610963 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crh |
corticotropin releasing hormone |
decreases abundance |
ISO |
CRH protein results in decreased abundance of anandamide |
CTD |
PMID:26821211 |
|
NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions increases metabolic processing |
ISO |
cannabichromene inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabidiol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; cannabigerol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Cannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; delta-8-tetrahydrocannabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide]; Dronabinol inhibits the reaction [CYP2J2 protein results in increased metabolism of anandamide] |
CTD |
PMID:29689453 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of DDIT3 mRNA; anandamide results in increased expression of DDIT3 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [anandamide results in increased expression of DDIT3 protein] |
CTD |
PMID:21949157 PMID:26513129 PMID:29441458 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Eif2s1 |
eukaryotic translation initiation factor 2 subunit alpha |
increases phosphorylation multiple interactions |
ISO |
anandamide results in increased phosphorylation of EIF2S1 protein 4-phenylbutyric acid inhibits the reaction [anandamide results in increased phosphorylation of EIF2S1 protein] |
CTD |
PMID:26513129 |
|
NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225
|
|
G |
Ervfrd-1 |
endogenous retrovirus group FRD member 1, envelope |
decreases expression |
ISO |
anandamide results in decreased expression of ERVFRD-1 mRNA |
CTD |
PMID:30610963 |
|
NCBI chr12:22,151,211...22,158,264
Ensembl chr12:22,151,211...22,158,264
|
|
G |
F3 |
coagulation factor III, tissue factor |
multiple interactions increases expression |
ISO |
anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] anandamide results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faah |
fatty acid amide hydrolase |
increases degradation increases response to substance decreases metabolic processing multiple interactions affects expression |
ISO EXP |
FAAH results in increased degradation of anandamide FAAH gene mutant form results in increased susceptibility to anandamide FAAH gene mutant form results in decreased metabolism of anandamide FAAH protein results in increased degradation of anandamide [Chlorpyrifos results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in increased abundance of anandamide; [Lipopolysaccharides results in decreased expression of FAAH protein] which results in increased abundance of anandamide; FAAH protein results in increased metabolism of and results in decreased activity of anandamide; Nitroglycerin promotes the reaction [FAAH protein results in increased degradation of anandamide]; Silybin inhibits the reaction [FAAH protein results in increased metabolism of and results in decreased activity of anandamide] anandamide affects the expression of FAAH protein [cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide]; [PF 3845 results in decreased activity of FAAH protein] which results in decreased metabolism of anandamide; Rimonabant inhibits the reaction [FAAH gene mutant form results in increased susceptibility to anandamide] |
CTD |
PMID:11556820 PMID:16131814 PMID:16886060 PMID:19515121 PMID:20702753 PMID:23761300 PMID:26642910 PMID:27307500 PMID:27385208 PMID:29787777 PMID:31121907 PMID:37245739 More...
|
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
multiple interactions affects abundance affects binding |
EXP ISO |
11-hydroxy-delta(9)-tetrahydrocannabinol inhibits the reaction [anandamide analog binds to FABP1 protein]; Dronabinol inhibits the reaction [anandamide analog binds to FABP1 protein] FABP1 protein affects the abundance of anandamide FABP1 protein affects the reaction [Dronabinol results in increased abundance of anandamide]; FABP1 protein affects the reaction [glyceryl 2-arachidonate results in increased abundance of anandamide] |
CTD |
PMID:29414765 PMID:30232874 |
|
NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
EXP |
anandamide inhibits the reaction [Nitroglycerin results in increased expression of FOS protein]; capsazepine inhibits the reaction [anandamide results in increased expression of FOS protein]; resiniferatoxin inhibits the reaction [anandamide results in increased expression of FOS protein] anandamide results in increased expression of FOS; anandamide results in increased expression of FOS protein |
CTD |
PMID:9748483 PMID:15601931 PMID:19515121 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF]; anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B] |
CTD |
PMID:12813001 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
increases expression |
ISO |
anandamide results in increased expression of IGF1 protein |
CTD |
PMID:17307377 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
[OMDM-1 cpd co-treated with anandamide] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein]; anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:15748152 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]; anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL1B protein]] anandamide inhibits the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of IL1B]; anandamide promotes the reaction [IL1B protein results in increased expression of F3 protein] |
CTD |
PMID:12813001 PMID:15748152 PMID:27556861 PMID:30611738 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Serotonin promotes the reaction [Dextran Sulfate results in increased expression of IL6 protein]] |
CTD |
PMID:30611738 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Lep |
leptin |
decreases abundance multiple interactions decreases activity decreases transport |
ISO |
LEP protein results in decreased abundance of anandamide Dietary Fats inhibits the reaction [LEP protein results in decreased abundance of anandamide] LEP protein results in decreased activity of anandamide LEP protein results in decreased transport of anandamide |
CTD |
PMID:16154199 PMID:29967158 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K1 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k2 |
mitogen activated protein kinase kinase 2 |
multiple interactions |
EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein; U 0126 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAP2K2 protein] |
CTD |
PMID:12657697 |
|
NCBI chr 7:8,590,729...8,610,279
Ensembl chr 7:8,580,905...8,610,243
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] anandamide results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK1 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; Rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 gene mutant form inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] anandamide results in increased phosphorylation of MAPK3 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; AM 251 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; Hydrogen Peroxide promotes the reaction [anandamide results in increased phosphorylation of MAPK3 protein]; JTE 907 inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Pertussis Toxin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; wortmannin inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] 8-Bromo Cyclic Adenosine Monophosphate inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein]; anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; rimonabant inhibits the reaction [anandamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12657697 PMID:19477951 PMID:21179406 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mmp1 |
matrix metallopeptidase 1 |
increases expression |
ISO |
anandamide results in increased expression of MMP1 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:4,658,588...4,679,099
Ensembl chr 8:4,658,588...4,679,097
|
|
G |
Mmp3 |
matrix metallopeptidase 3 |
increases expression |
ISO |
anandamide results in increased expression of MMP3 mRNA |
CTD |
PMID:16330497 |
|
NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of MMP9 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; anandamide inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] |
CTD |
PMID:11891798 PMID:15748152 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage |
ISO |
anandamide results in increased cleavage of PARP1 protein |
CTD |
PMID:29441458 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
anandamide binds to and results in increased activity of PPARA protein |
CTD |
PMID:17906680 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing |
EXP ISO |
[nimesulide results in decreased expression of PTGS2] which results in increased activity of anandamide anandamide results in increased expression of PTGS2 mRNA; anandamide results in increased expression of PTGS2 protein PTGS2 results in increased metabolism of anandamide [nimesulide results in decreased expression of PTGS2] promotes the reaction [FAAH affects the metabolism of anandamide] |
CTD |
PMID:16330497 PMID:17245358 PMID:20702753 |
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Selp |
selectin P |
multiple interactions increases expression |
ISO |
anandamide inhibits the reaction [thrombin receptor-activating peptide SFLLRNPNDKY results in increased expression of SELP protein] anandamide results in increased expression of SELP protein |
CTD |
PMID:27151562 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
increases expression multiple interactions |
ISO |
anandamide results in increased expression of TIMP1 mRNA N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [anandamide results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16330497 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance |
EXP ISO |
anandamide inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of TNF protein] anandamide inhibits the reaction [[Serotonin co-treated with Dextran Sulfate] results in increased expression of TNF protein] TNF protein results in increased abundance of anandamide anandamide affects the reaction [[Lipopolysaccharides co-treated with IFNG] results in increased secretion of TNF] |
CTD |
PMID:12509806 PMID:12813001 PMID:20626112 PMID:30611738 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions increases response to substance increases activity affects response to substance affects binding |
ISO EXP |
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; capsazepine inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; CNR1 affects the reaction [TRPV1 affects the susceptibility to anandamide]; CNR2 affects the reaction [TRPV1 affects the susceptibility to anandamide]; Egtazic Acid inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; methyl arachidonylfluorophosphonate promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; N-(2-methyl-3-hydroxyphenyl)-5,8,11,14-eicosatetraenamide inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Nitroprusside promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; Phenylmethylsulfonyl Fluoride promotes the reaction [anandamide binds to and results in increased activity of TRPV1 protein]; rimonabant inhibits the reaction [anandamide binds to and results in increased activity of TRPV1 protein] TRPV1 protein results in increased susceptibility to anandamide anandamide results in increased activity of TRPV1 protein 3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [anandamide promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; anandamide binds to and results in increased activity of TRPV1 protein; bisindolylmaleimide inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Eicosapentaenoic Acid inhibits the reaction [anandamide results in increased activity of TRPV1 protein]; Tetradecanoylphorbol Acetate promotes the reaction [anandamide results in increased activity of TRPV1 protein] anandamide binds to TRPV1 protein |
CTD |
PMID:11140687 PMID:11278420 PMID:14504685 PMID:15453094 PMID:15601931 PMID:15615864 PMID:17038422 PMID:17913835 PMID:18550765 PMID:21949157 More...
|
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
anandamide results in decreased expression of and results in decreased secretion of VEGFA protein |
CTD |
PMID:15313899 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions increases degradation |
ISO |
Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Arachidonic Acid results in increased degradation of ABCA1 protein |
CTD |
PMID:16118212 |
|
NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170
|
|
G |
Abcb11 |
ATP binding cassette subfamily B member 11 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [GW 4064 results in increased expression of ABCB11 mRNA] |
CTD |
PMID:15307955 |
|
NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ABCD3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:209,852,087...209,905,763
Ensembl chr 2:209,852,087...209,906,020
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ABCG1 mRNA |
CTD |
PMID:16730733 |
|
NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948
|
|
G |
Adarb1 |
adenosine deaminase, RNA-specific, B1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ADARB1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:11,222,569...11,350,854
Ensembl chr20:11,222,583...11,350,852
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
Eicosapentaenoic Acid inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid]; Quinacrine inhibits the reaction [AGT protein results in increased metabolism of and results in increased abundance of Arachidonic Acid] |
CTD |
PMID:16257180 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]] |
CTD |
PMID:19162293 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
increases phosphorylation multiple interactions |
ISO |
Arachidonic Acid results in increased phosphorylation of AKT1 protein aristolochic acid I inhibits the reaction [Arachidonic Acid results in increased phosphorylation of AKT1 protein] |
CTD |
PMID:19344371 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox12 |
arachidonate 12-lipoxygenase, 12S type |
affects response to substance increases metabolic processing |
ISO |
ALOX12 protein affects the susceptibility to Arachidonic Acid ALOX12 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:17027136 PMID:19373248 |
|
NCBI chr10:54,958,263...54,970,542
Ensembl chr10:54,958,271...54,970,542
|
|
G |
Alox12b |
arachidonate 12-lipoxygenase, 12R type |
multiple interactions |
ISO |
[TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid |
CTD |
PMID:30258081 |
|
NCBI chr10:53,863,060...53,874,938
Ensembl chr10:53,863,060...53,874,938
|
|
G |
Alox15 |
arachidonate 15-lipoxygenase |
affects metabolic processing multiple interactions increases metabolic processing |
ISO |
ALOX15 protein affects the metabolism of Arachidonic Acid [ALOX15 protein affects the metabolism of Arachidonic Acid] which affects the susceptibility to Acetylcholine; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,12,15-trihydroxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 11,14,15-trihydroxyeicosa-5,8,12-trienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-11,12-epoxyeicosatrienoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 15-hydroxy-5,8,11,13-eicosatetraenoic acid; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of 6-Ketoprostaglandin F1 alpha; [ALOX15 protein affects the metabolism of Arachidonic Acid] which results in increased abundance of Dinoprostone; ALOX15 protein results in increased metabolism of and affects the susceptibility to Arachidonic Acid ALOX15 protein results in increased metabolism of Arachidonic Acid [IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA |
CTD |
PMID:8305483 PMID:11861792 PMID:21193584 PMID:23872364 |
|
NCBI chr10:55,060,169...55,068,885
Ensembl chr10:55,060,412...55,068,874
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions increases metabolic processing |
ISO |
[sodium arsenite co-treated with Platelet Activating Factor co-treated with Arachidonic Acid] results in increased phosphorylation of and results in increased activity of ALOX5 protein; [Sorbitol co-treated with Calcimycin co-treated with Arachidonic Acid] affects the localization of ALOX5 protein; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which affects the abundance of Arachidonic Acid; [zileuton results in decreased activity of ALOX5 protein] which results in decreased susceptibility to Arachidonic Acid; Arachidonic Acid inhibits the reaction [L 708714 binds to ALOX5 protein]; CJ 13610 inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid]; zileuton inhibits the reaction [ALOX5 protein results in increased metabolism of Arachidonic Acid] |
CTD |
PMID:7577949 PMID:7592874 PMID:9495842 PMID:10779545 PMID:11698504 PMID:18295198 PMID:30258081 More...
|
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Apoa1 |
apolipoprotein A1 |
multiple interactions decreases expression |
ISO |
Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Cholesterol]]; Arachidonic Acid inhibits the reaction [APOA1 protein affects the reaction [ABCA1 protein results in increased transport of Phospholipids]] Arachidonic Acid results in decreased expression of APOA1 mRNA |
CTD |
PMID:7983038 PMID:16118212 |
|
NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035
|
|
G |
Apoc1 |
apolipoprotein C1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of APOC1 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 1:79,347,057...79,350,340
Ensembl chr 1:79,346,136...79,350,375
|
|
G |
Apoe |
apolipoprotein E |
multiple interactions decreases response to substance |
ISO |
APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; Aspirin inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; tempol inhibits the reaction [APOE gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] Aspirin inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid]; tempol inhibits the reaction [APOE gene mutant form results in decreased susceptibility to Arachidonic Acid] |
CTD |
PMID:20530721 |
|
NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932
|
|
G |
App |
amyloid beta precursor protein |
increases secretion multiple interactions |
ISO |
APP protein modified form results in increased secretion of Arachidonic Acid [1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of AQP3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
increases expression |
ISO |
Arachidonic Acid results in increased expression of ARHGDIA mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Atf1 |
activating transcription factor 1 |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [Quercetin results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:20551291 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atf2 |
activating transcription factor 2 |
multiple interactions increases phosphorylation |
ISO |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of ATF2 protein] |
CTD |
PMID:19720122 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of ATF3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631
|
|
G |
Avp |
arginine vasopressin |
increases abundance |
EXP |
AVP protein results in increased abundance of Arachidonic Acid |
CTD |
PMID:11356622 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAD protein] |
CTD |
PMID:30626086 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Barx1 |
BARX homeobox 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of BARX1 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr17:15,990,412...15,993,887
Ensembl chr17:15,990,412...15,993,887
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions affects localization |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of BAX protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid affects the localization of BAX protein] |
CTD |
PMID:19540902 PMID:19720122 PMID:30626086 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Arachidonic Acid results in decreased expression of BCL2 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2 protein] |
CTD |
PMID:19540902 PMID:19620254 PMID:19720122 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions decreases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; [Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein; benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein]; pyrazolanthrone inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19540902 PMID:19620254 PMID:19720122 PMID:27916511 PMID:30626086 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of BDNF mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage multiple interactions |
ISO |
Arachidonic Acid results in increased cleavage of BID protein FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein] |
CTD |
PMID:19720122 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases degradation |
ISO |
Arachidonic Acid results in increased activity of CASP3 protein 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased degradation of CASP3 protein alternative form]; [Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein; [Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form; Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased cleavage of CASP3 protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of CASP3 protein modified form]; Resveratrol inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in decreased expression of CASP3 protein] |
CTD |
PMID:16704987 PMID:19540902 PMID:19620254 PMID:19720122 PMID:23266427 PMID:27916511 PMID:30626086 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp8 |
caspase 8 |
multiple interactions increases activity |
ISO |
FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein] |
CTD |
PMID:19720122 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity |
ISO |
Arachidonic Acid results in increased activity of CASP9 protein |
CTD |
PMID:19540902 PMID:19720122 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
increases activity |
EXP |
Arachidonic Acid results in increased activity of CAT protein |
CTD |
PMID:7548195 PMID:16982041 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Cd40 |
CD40 molecule |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of CD40 mRNA] |
CTD |
PMID:15684433 |
|
NCBI chr 3:153,790,372...153,805,279
Ensembl chr 3:153,790,449...153,805,534
|
|
G |
Ces1d |
carboxylesterase 1D |
decreases activity multiple interactions |
ISO EXP |
Arachidonic Acid results in decreased activity of CES1 protein [Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein]; gallocatechol inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein] [Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein; [CES1 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid; epigallocatechin gallate inhibits the reaction [[Arachidonic Acid co-treated with ferric chloride] results in decreased activity of CES1 protein] |
CTD |
PMID:19761868 PMID:21049984 PMID:37353134 |
|
NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035
|
|
G |
Ces2h |
carboxylesterase 2H |
multiple interactions |
ISO |
[CES2 protein results in increased hydrolysis of glyceryl 2-arachidonate] which results in increased chemical synthesis of Arachidonic Acid |
CTD |
PMID:21049984 |
|
NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830
|
|
G |
Cnr2 |
cannabinoid receptor 2 |
multiple interactions |
ISO |
CNR2 protein affects the reaction [Arachidonic Acid results in increased expression of CXCL8 protein] |
CTD |
PMID:15115777 |
|
NCBI chr 5:148,125,222...148,151,548
Ensembl chr 5:148,125,604...148,151,548
|
|
G |
Col18a1 |
collagen type XVIII alpha 1 chain |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of COL18A1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:11,474,104...11,582,593
Ensembl chr20:11,474,104...11,582,593
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
increases expression |
ISO |
Arachidonic Acid results in increased expression of CPT1A mRNA |
CTD |
PMID:15307955 |
|
NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
increases phosphorylation multiple interactions |
EXP |
Arachidonic Acid results in increased phosphorylation of CREB1 protein Ketoconazole inhibits the reaction [Arachidonic Acid results in increased phosphorylation of CREB1 protein] |
CTD |
PMID:17680988 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Csk |
C-terminal Src kinase |
increases activity affects localization |
ISO |
Arachidonic Acid results in increased activity of CSK protein Arachidonic Acid affects the localization of CSK protein |
CTD |
PMID:18388244 |
|
NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292
|
|
G |
Ctdspl |
CTD small phosphatase like |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of CTDSPL mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 8:118,642,729...118,767,238
Ensembl chr 8:118,642,672...118,767,117
|
|
G |
Cycs |
cytochrome c, somatic |
affects localization |
ISO |
Arachidonic Acid affects the localization of CYCS protein |
CTD |
PMID:19720122 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054 Ensembl chr18:79,651,378...79,654,054
|
|
G |
Cygb |
cytoglobin |
multiple interactions |
EXP |
CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA]; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA]; CYGB protein results in decreased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid] |
CTD |
PMID:16581302 |
|
NCBI chr10:101,877,675...101,887,442
Ensembl chr10:101,877,676...101,887,442
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
affects metabolic processing multiple interactions |
ISO |
CYP1A1 protein affects the metabolism of Arachidonic Acid Arachidonic Acid inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of CYP1A1 mRNA] |
CTD |
PMID:15258110 PMID:19063610 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
increases metabolic processing decreases activity |
ISO |
CYP1A2 protein results in increased metabolism of Arachidonic Acid Arachidonic Acid results in decreased activity of CYP1A2 protein |
CTD |
PMID:12675279 PMID:16978661 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp1b1 |
cytochrome P450, family 1, subfamily b, polypeptide 1 |
affects metabolic processing |
ISO |
CYP1B1 protein affects the metabolism of Arachidonic Acid |
CTD |
PMID:15258110 |
|
NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917
|
|
G |
Cyp24a1 |
cytochrome P450, family 24, subfamily a, polypeptide 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of CYP24A1 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
increases metabolic processing |
ISO |
CYP2B6 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:12675279 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2c6 |
cytochrome P450, family 2, subfamily C, polypeptide 6 |
decreases activity increases metabolic processing multiple interactions |
ISO |
Arachidonic Acid results in decreased activity of CYP2C19 protein CYP2C19 protein results in increased metabolism of Arachidonic Acid CYP2C19 gene SNP affects the susceptibility to [Adenosine Diphosphate co-treated with Arachidonic Acid]; CYP2C19 protein results in increased metabolism of [Arachidonic Acid co-treated with NADP] |
CTD |
PMID:12675279 PMID:16978661 PMID:18004210 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases metabolic processing |
ISO |
CYP2C8 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:12675279 |
|
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
increases metabolic processing |
ISO |
CYP2D6 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:12675279 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
multiple interactions affects hydroxylation increases response to substance decreases activity |
ISO EXP |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein; [[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein; [Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; allyl sulfide inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; Cadmium Chloride affects the reaction [CYP2E1 protein results in increased susceptibility to Arachidonic Acid]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]; CYP2E1 results in increased susceptibility to [Arachidonic Acid co-treated with Zinc Sulfate]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [CYP2E1 protein results in increased susceptibility to [ferric nitrilotriacetate co-treated with Arachidonic Acid]]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Zinc Sulfate inhibits the reaction [CYP2E1 results in increased susceptibility to Arachidonic Acid] CYP2E1 protein affects the hydroxylation of Arachidonic Acid Arachidonic Acid results in decreased activity of CYP2E1 protein |
CTD |
PMID:12086689 PMID:12566070 PMID:15205388 PMID:16978661 PMID:17034788 PMID:21352821 PMID:22486562 More...
|
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp2j4 |
cytochrome P450, family 2, subfamily j, polypeptide 4 |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [CYP2J2 protein results in decreased methylation of Astemizole] |
CTD |
PMID:12386130 |
|
NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
multiple interactions increases metabolic processing decreases activity |
ISO |
Ketoconazole inhibits the reaction [CYP3A4 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in decreased activity of CYP3A4 protein |
CTD |
PMID:12675279 PMID:16978661 |
|
NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
multiple interactions increases hydroxylation |
ISO |
rubiarbonone C inhibits the reaction [CYP4F3 protein alternative form results in increased hydroxylation of Arachidonic Acid] |
CTD |
PMID:30259074 |
|
NCBI chr16:17,763,543...17,804,944
Ensembl chr16:17,707,317...17,804,940
|
|
G |
Dct |
dopachrome tautomerase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of DCT mRNA |
CTD |
PMID:16623957 |
|
NCBI chr15:95,062,006...95,100,863
Ensembl chr15:95,062,003...95,100,836
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of DDIT4 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddx24 |
DEAD-box helicase 24 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of DDX24 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:122,564,767...122,582,032
Ensembl chr 6:122,564,767...122,581,927
|
|
G |
Des |
desmin |
increases expression |
EXP |
Arachidonic Acid results in increased expression of DES mRNA |
CTD |
PMID:19089455 |
|
NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699
|
|
G |
Dhcr7 |
7-dehydrocholesterol reductase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of DHCR7 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055
|
|
G |
Ebp |
EBP, cholestenol delta-isomerase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of EBP mRNA |
CTD |
PMID:16704987 |
|
NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826
|
|
G |
Egfr |
epidermal growth factor receptor |
multiple interactions |
EXP |
5,8,11,14-Eicosatetraynoic Acid inhibits the reaction [Arachidonic Acid results in increased phosphorylation of and results in increased activity of EGFR protein] |
CTD |
PMID:15525798 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of EGR1 mRNA |
CTD |
PMID:8764118 PMID:16704987 |
|
NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766
|
|
G |
Eif4ebp3 |
eukaryotic translation initiation factor 4E binding protein 3 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Quercetin results in decreased phosphorylation of EIF4EBP3 protein] |
CTD |
PMID:20551291 |
|
NCBI chr18:28,263,089...28,268,033
Ensembl chr18:28,162,311...28,268,024
|
|
G |
Ephx2 |
epoxide hydrolase 2 |
increases metabolic processing |
ISO |
EPHX2 protein results in increased metabolism of Arachidonic Acid |
CTD |
PMID:26165641 |
|
NCBI chr15:40,289,901...40,327,632
Ensembl chr15:40,289,902...40,327,615
|
|
G |
Erg28 |
ergosterol biosynthesis 28 homolog |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ERG28 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:105,474,112...105,483,078
Ensembl chr 6:105,474,113...105,483,078
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
Arachidonic Acid results in increased expression of F3 protein |
CTD |
PMID:27556861 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Faah |
fatty acid amide hydrolase |
multiple interactions increases chemical synthesis |
EXP |
Nitroglycerin promotes the reaction [FAAH protein results in increased chemical synthesis of Arachidonic Acid] |
CTD |
PMID:19515121 |
|
NCBI chr 5:129,479,774...129,499,018
Ensembl chr 5:129,479,824...129,498,677
|
|
G |
Fadd |
Fas associated via death domain |
multiple interactions |
ISO |
FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP3 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased activity of CASP8 protein]; FADD protein promotes the reaction [Arachidonic Acid results in increased cleavage of BID protein] |
CTD |
PMID:19720122 |
|
NCBI chr 1:199,743,200...199,745,746
Ensembl chr 1:199,739,994...199,745,653
|
|
G |
Fads1 |
fatty acid desaturase 1 |
multiple interactions |
ISO |
[geraniol results in decreased activity of FADS1 protein] which results in decreased chemical synthesis of Arachidonic Acid |
CTD |
PMID:16462894 |
|
NCBI chr 1:206,827,724...206,842,734
Ensembl chr 1:206,827,765...206,842,734
|
|
G |
Fads2 |
fatty acid desaturase 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of FADS2 mRNA |
CTD |
PMID:21457203 |
|
NCBI chr 1:206,707,384...206,747,333
Ensembl chr 1:206,708,783...206,748,789
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein] Arachidonic Acid results in increased expression of FAS mRNA; Arachidonic Acid results in increased expression of FAS protein |
CTD |
PMID:19720122 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein] Arachidonic Acid results in increased expression of FASLG mRNA; Arachidonic Acid results in increased expression of FASLG protein |
CTD |
PMID:19720122 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Fasn |
fatty acid synthase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of FASN mRNA |
CTD |
PMID:19159447 |
|
NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of FGFR3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression decreases phosphorylation |
ISO |
[Arachidonic Acid co-treated with Quercetin co-treated with benzyloxycarbonylleucyl-leucyl-leucine aldehyde] results in decreased expression of FOS protein; Arachidonic Acid inhibits the reaction [Quercetin results in increased expression of FOS protein]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of FOS mRNA] Arachidonic Acid results in decreased phosphorylation of FOS protein |
CTD |
PMID:8764118 PMID:10864209 PMID:15878913 PMID:16704987 PMID:19720122 PMID:20551291 More...
|
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fosl1 |
FOS like 1, AP-1 transcription factor subunit |
increases expression |
ISO |
Arachidonic Acid results in increased expression of FOSL1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:202,754,549...202,763,057
Ensembl chr 1:202,754,529...202,764,930
|
|
G |
Gap43 |
growth associated protein 43 |
increases phosphorylation |
ISO |
Arachidonic Acid results in increased phosphorylation of GAP43 protein |
CTD |
PMID:9852580 |
|
NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression increases activity |
ISO |
Arachidonic Acid results in increased expression of GCLC mRNA Arachidonic Acid results in increased activity of GCLC protein |
CTD |
PMID:16704987 PMID:17092368 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
increases expression |
ISO EXP |
Arachidonic Acid results in increased expression of GCLM mRNA Arachidonic Acid metabolite results in increased expression of GCLM mRNA |
CTD |
PMID:16704987 PMID:27012417 |
|
NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535
|
|
G |
Glrx |
glutaredoxin |
affects response to substance |
ISO |
GLRX protein affects the susceptibility to Arachidonic Acid |
CTD |
PMID:19373248 |
|
NCBI chr 2:5,341,873...5,351,686
Ensembl chr 2:5,341,885...5,351,680
|
|
G |
Gnpda1 |
glucosamine-6-phosphate deaminase 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of GNPDA1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr18:30,165,435...30,177,462
Ensembl chr18:30,165,427...30,177,486
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
ISO |
Drugs, Chinese Herbal inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein]; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of ALT protein] |
CTD |
PMID:27916511 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
ISO |
[Iodoacetates results in decreased activity of GPX1 protein] which affects the metabolism of Arachidonic Acid |
CTD |
PMID:11115402 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
multiple interactions |
ISO |
[Iodoacetates results in decreased activity of GPX4 protein] which affects the metabolism of Arachidonic Acid; Arachidonic Acid promotes the reaction [Sodium Selenite results in increased expression of and results in increased activity of GPX4 protein] |
CTD |
PMID:11115402 PMID:14642406 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[SB 216763 results in decreased activity of GSK3B protein] results in decreased susceptibility to [Arachidonic Acid co-treated with Iron] |
CTD |
PMID:19620254 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of HMGCR mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:27,997,523...28,018,983
Ensembl chr 2:27,997,525...28,019,703
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions decreases response to substance |
ISO EXP |
Arachidonic Acid results in increased expression of HMOX1 mRNA Arachidonic Acid metabolite results in increased expression of HMOX1 mRNA; Arachidonic Acid metabolite results in increased expression of HMOX1 protein NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein] HMOX1 protein results in decreased susceptibility to Arachidonic Acid |
CTD |
PMID:15036350 PMID:16704987 PMID:17092368 PMID:27012417 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hs2st1 |
heparan sulfate 2-O-sulfotransferase 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of HS2ST1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:233,508,018...233,641,769
Ensembl chr 2:233,508,021...233,641,769
|
|
G |
Hsp90ab1 |
heat shock protein 90 alpha family class B member 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of HSP90AB1 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488
|
|
G |
Htr1a |
5-hydroxytryptamine receptor 1A |
multiple interactions |
ISO |
Arachidonic Acid metabolite inhibits the reaction [HTR1A protein inhibits the reaction [Colforsin results in increased abundance of Cyclic AMP]] |
CTD |
PMID:11356925 |
|
NCBI chr 2:36,693,462...36,698,026
Ensembl chr 2:36,694,174...36,695,442
|
|
G |
Id3 |
inhibitor of DNA binding 3 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ID3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:148,372,784...148,374,353
Ensembl chr 5:148,372,762...148,374,349
|
|
G |
Idi1 |
isopentenyl-diphosphate delta isomerase 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of IDI1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr17:61,629,592...61,637,357
Ensembl chr17:61,629,594...61,637,357
|
|
G |
Ift25 |
intraflagellar transport 25 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of IFT25 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:122,035,588...122,062,421
Ensembl chr 5:122,035,581...122,062,421
|
|
G |
Igfbp7 |
insulin-like growth factor binding protein 7 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of IGFBP7 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr14:30,737,414...30,797,317
Ensembl chr14:30,737,164...30,797,314
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of IL12B mRNA] |
CTD |
PMID:15684433 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[IL1A protein co-treated with Arachidonic Acid] results in increased abundance of Dinoprostone |
CTD |
PMID:11351503 |
|
NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein] |
CTD |
PMID:11112151 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
[IL4 protein co-treated with Arachidonic Acid] results in increased activity of ALOX15 protein; [IL4 protein co-treated with Arachidonic Acid] results in increased expression of ALOX15 mRNA |
CTD |
PMID:11861792 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Il6 |
interleukin 6 |
increases secretion |
ISO |
Arachidonic Acid results in increased secretion of IL6 protein |
CTD |
PMID:20436887 PMID:21457203 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ilvbl |
ilvB acetolactate synthase like |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ILVBL mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:11,039,870...11,049,924
Ensembl chr 7:11,039,871...11,049,924
|
|
G |
Ins2 |
insulin 2 |
increases secretion multiple interactions |
ISO |
Arachidonic Acid results in increased secretion of INS protein Arachidonic Acid promotes the reaction [Glucose results in increased secretion of INS protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide promotes the reaction [Arachidonic Acid results in increased secretion of INS protein]; phenidone promotes the reaction [Arachidonic Acid results in increased secretion of INS protein] |
CTD |
PMID:17192482 |
|
NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775
|
|
G |
Isl1 |
ISL LIM homeobox 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of ISL1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:48,079,412...48,090,704
Ensembl chr 2:48,080,522...48,095,584
|
|
G |
Itga2b |
integrin subunit alpha 2b |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of ITGA2B protein Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGA2B protein]] |
CTD |
PMID:18413191 |
|
NCBI chr10:87,408,532...87,426,055
Ensembl chr10:87,408,536...87,426,168
|
|
G |
Itga6 |
integrin subunit alpha 6 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of ITGA6 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:56,604,512...56,689,428
Ensembl chr 3:56,617,268...56,689,428
|
|
G |
Itgb3 |
integrin subunit beta 3 |
multiple interactions increases expression |
ISO |
Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of ITGB3 protein] |
CTD |
PMID:18413191 PMID:23249183 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of JUN mRNA Arachidonic Acid results in increased expression of and results in increased phosphorylation of JUN protein; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FAS protein]; JUN protein affects the reaction [Arachidonic Acid results in increased expression of FASLG protein] |
CTD |
PMID:8764118 PMID:16704987 PMID:19720122 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Junb |
JunB proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine inhibits the reaction [Arachidonic Acid analog results in increased expression of JUNB mRNA] Arachidonic Acid results in increased expression of JUNB mRNA |
CTD |
PMID:8764118 |
|
NCBI chr19:23,176,265...23,178,049
Ensembl chr19:23,176,294...23,178,035
|
|
G |
Kcnk10 |
potassium two pore domain channel subfamily K member 10 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr 6:117,690,052...117,826,120
Ensembl chr 6:117,694,222...117,825,695
|
|
G |
Kcnk2 |
potassium two pore domain channel subfamily K member 2 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [KCNK2 protein results in increased transport of Potassium] |
CTD |
PMID:16075240 |
|
NCBI chr13:100,766,101...100,963,435
Ensembl chr13:100,766,113...100,963,435
|
|
G |
Kcnk4 |
potassium two pore domain channel subfamily K member 4 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [KCNK4 protein results in increased transport of Potassium] |
CTD |
PMID:10767409 PMID:16075240 |
|
NCBI chr 1:204,117,941...204,129,494
Ensembl chr 1:204,114,572...204,125,925
|
|
G |
Klf5 |
KLF transcription factor 5 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of KLF5 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445
|
|
G |
Klf6 |
KLF transcription factor 6 |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of KLF6 mRNA; Arachidonic Acid results in increased expression of KLF6 mRNA alternative form; Arachidonic Acid results in increased expression of KLF6 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; [Arachidonic Acid co-treated with Hydrogen Peroxide] results in increased expression of KLF6 protein; [Arachidonic Acid co-treated with SB 203580] results in decreased expression of KLF6 mRNA; [Arachidonic Acid co-treated with Vitamin K 3] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Hydrogen Peroxide co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; [CYP2E1 protein co-treated with Vitamin K 3 co-treated with Arachidonic Acid] results in increased expression of KLF6 protein; allyl sulfide inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; allyl sulfide inhibits the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; allyl sulfide inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Arachidonic Acid inhibits the reaction [CYP2E1 protein results in decreased expression of KLF6 mRNA alternative form]; Arachidonic Acid inhibits the reaction [pyrazolanthrone results in decreased expression of KLF6 mRNA]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA alternative form]; Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]; CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]; pyrazolanthrone inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; SB 203580 promotes the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]]; Vitamin E inhibits the reaction [CYP2E1 protein promotes the reaction [Arachidonic Acid results in increased expression of KLF6 mRNA alternative form]]; Wortmannin inhibits the reaction [Arachidonic Acid promotes the reaction [CYP2E1 protein results in increased expression of KLF6 mRNA]] |
CTD |
PMID:22486562 |
|
NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570
|
|
G |
Kng1 |
kininogen 1 |
multiple interactions |
ISO |
Arachidonic Acid inhibits the reaction [GW 4064 results in increased expression of KNG1 mRNA] |
CTD |
PMID:15307955 |
|
NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555
|
|
G |
Krt18 |
keratin 18 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT18 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:133,157,486...133,161,162
Ensembl chr 7:133,157,475...133,161,166
|
|
G |
Krt8 |
keratin 8 |
multiple interactions |
ISO |
[[Arachidonic Acid co-treated with ferric nitrilotriacetate co-treated with Ethanol] results in increased expression of CYP2E1 protein] which results in increased expression of KRT8 protein |
CTD |
PMID:17034788 |
|
NCBI chr 7:133,124,203...133,131,656
Ensembl chr 7:133,124,203...133,131,728
|
|
G |
Lamp2 |
lysosomal-associated membrane protein 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of LAMP2 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522
|
|
G |
Ldlr |
low density lipoprotein receptor |
multiple interactions decreases response to substance |
ISO |
Aspirin inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; dazoxiben inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]]; LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]; tempol inhibits the reaction [LDLR gene mutant form promotes the reaction [Arachidonic Acid results in increased abundance of 11-dehydro-thromboxane B2]] LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid Aspirin inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; dazoxiben inhibits the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid]; Indomethacin promotes the reaction [LDLR gene mutant form results in decreased susceptibility to Arachidonic Acid] |
CTD |
PMID:20530721 |
|
NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580
|
|
G |
Lep |
leptin |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of LEP mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262
|
|
G |
Lipc |
lipase C, hepatic type |
decreases abundance multiple interactions |
ISO |
LIPC gene mutant form results in decreased abundance of Arachidonic Acid [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
decreases abundance multiple interactions |
ISO |
LIPG gene mutant form results in decreased abundance of Arachidonic Acid [LIPC gene mutant form co-treated with LIPG gene mutant form] results in decreased abundance of Arachidonic Acid |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
G |
Lrat |
lecithin retinol acyltransferase |
increases expression |
EXP |
Arachidonic Acid results in increased expression of LRAT mRNA |
CTD |
PMID:12576510 |
|
NCBI chr 2:168,264,093...168,273,155
Ensembl chr 2:168,266,877...168,273,619
|
|
G |
Lss |
lanosterol synthase |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of LSS mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:12,091,138...12,118,858
Ensembl chr20:12,092,774...12,118,762
|
|
G |
Ltb4r |
leukotriene B4 receptor |
affects response to substance |
ISO |
LTB4R1 protein affects the susceptibility to Arachidonic Acid |
CTD |
PMID:10934231 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G |
Luc7l3 |
LUC7-like 3 pre-mRNA splicing factor |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of LUC7L3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:79,240,050...79,276,555
Ensembl chr10:79,240,563...79,276,538
|
|
G |
Maff |
MAF bZIP transcription factor F |
increases expression |
ISO |
Arachidonic Acid results in increased expression of MAFF mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]]; FOS protein affects the reaction [MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein]]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FAS protein]; MAP2K1 protein inhibits the reaction [Arachidonic Acid results in increased expression of FASLG protein] |
CTD |
PMID:19720122 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation affects abundance multiple interactions |
ISO EXP |
Arachidonic Acid results in increased phosphorylation of MAPK1 protein MAPK1 protein affects the abundance of Arachidonic Acid [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:16216387 PMID:19464254 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO EXP |
MAPK14 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK14 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein] MAPK14 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid] |
CTD |
PMID:16120751 PMID:19540902 |
|
NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions affects abundance increases phosphorylation |
ISO EXP |
[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein]; CYP2C23 mRNA promotes the reaction [Arachidonic Acid results in increased phosphorylation of MAPK3 protein] MAPK3 protein affects the abundance of Arachidonic Acid |
CTD |
PMID:16216387 PMID:19464254 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapk8 |
mitogen-activated protein kinase 8 |
multiple interactions |
ISO |
MAPK8 mutant form inhibits the reaction [Arachidonic Acid affects the localization of BAX protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2 protein]; MAPK8 mutant form inhibits the reaction [Arachidonic Acid results in decreased expression of BCL2L1 protein] |
CTD |
PMID:19540902 |
|
NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981
|
|
G |
Mapt |
microtubule-associated protein tau |
increases phosphorylation multiple interactions |
ISO |
Arachidonic Acid results in increased phosphorylation of MAPT protein Ro 31-8220 inhibits the reaction [Arachidonic Acid results in increased phosphorylation of MAPT protein] |
CTD |
PMID:12605413 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases secretion multiple interactions increases expression |
ISO |
Arachidonic Acid results in increased secretion of MMP13 protein Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP13 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP13 protein] |
CTD |
PMID:16185265 |
|
NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases expression increases secretion |
ISO |
Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP2 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP2 protein] |
CTD |
PMID:16185265 |
|
NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
increases expression multiple interactions increases secretion |
ISO |
Arachidonic Acid results in increased expression of MMP9 mRNA Isotretinoin inhibits the reaction [Arachidonic Acid results in increased expression of MMP9 mRNA]; Isotretinoin inhibits the reaction [Arachidonic Acid results in increased secretion of MMP9 protein] |
CTD |
PMID:16185265 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Mpo |
myeloperoxidase |
increases secretion multiple interactions increases expression |
ISO |
Arachidonic Acid results in increased secretion of MPO protein 5-((1,5-bis(4-methoxyphenyl)pyrazol-3-yl)dimethoxymethyl)-2-chlorobenzamide inhibits the reaction [Arachidonic Acid results in increased expression of MPO protein] |
CTD |
PMID:3111576 PMID:9831321 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Mt2A |
metallothionein 2A |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Zinc Sulfate results in increased expression of MT2A mRNA] |
CTD |
PMID:12566070 |
|
NCBI chr19:10,832,009...10,832,783
Ensembl chr19:10,832,002...10,832,784
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions |
ISO |
[Quercetin co-treated with Arachidonic Acid] results in decreased phosphorylation of MTOR protein |
CTD |
PMID:20551291 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions increases localization |
ISO |
Adiponectin inhibits the reaction [Arachidonic Acid results in increased localization of NCF1 protein]; Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF1 protein] |
CTD |
PMID:12101222 PMID:20832062 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ncf2 |
neutrophil cytosolic factor 2 |
multiple interactions |
ISO |
Arachidonic Acid affects the reaction [Zymosan analog affects the localization of NCF2 protein] |
CTD |
PMID:12101222 |
|
NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions increases expression |
EXP |
NFE2L2 gene mutant form inhibits the reaction [Arachidonic Acid metabolite results in increased expression of HMOX1 protein] Arachidonic Acid metabolite results in increased expression of NFE2L2 protein |
CTD |
PMID:27012417 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Ngf |
nerve growth factor |
multiple interactions |
EXP |
NGF protein inhibits the reaction [Arachidonic Acid results in increased expression of TFRC protein] |
CTD |
PMID:17551831 |
|
NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
Arachidonic Acid results in increased cleavage of and results in increased secretion of NOX1 protein; Cholesterol, LDL affects the reaction [Adiponectin inhibits the reaction [Arachidonic Acid results in increased cleavage of NOX1 protein]] |
CTD |
PMID:20832062 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
EXP |
Arachidonic Acid metabolite results in increased expression of NQO1 mRNA |
CTD |
PMID:27012417 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr1h4 |
nuclear receptor subfamily 1, group H, member 4 |
affects binding multiple interactions |
ISO |
Arachidonic Acid binds to NR1H4 protein Arachidonic Acid inhibits the reaction [Chenodeoxycholic Acid results in increased activity of NR1H4 protein] |
CTD |
PMID:15307955 |
|
NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047
|
|
G |
Nr2f1 |
nuclear receptor subfamily 2, group F, member 1 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of NR2F1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:8,040,375...8,050,123
Ensembl chr 2:8,040,377...8,050,123
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of NR4A2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nr5a2 |
nuclear receptor subfamily 5, group A, member 2 |
multiple interactions decreases chemical synthesis |
ISO |
[NR5A2 gene mutant form results in increased susceptibility to Dietary Fats] which results in decreased abundance of Arachidonic Acid analog NR5A2 gene mutant form results in decreased chemical synthesis of Arachidonic Acid |
CTD |
PMID:29515023 |
|
NCBI chr13:48,313,634...48,433,494
Ensembl chr13:48,316,301...48,433,326
|
|
G |
Nrtn |
neurturin |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of NRTN mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 9:1,581,860...1,587,835
Ensembl chr 9:1,581,975...1,583,102
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Arachidonic Acid results in increased cleavage of PARP1 protein]; [Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form; Plant Extracts inhibits the reaction [[Arachidonic Acid co-treated with Iron] results in increased expression of PARP1 protein modified form] |
CTD |
PMID:10403056 PMID:19540902 PMID:21132278 PMID:30626086 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pde4dip |
phosphodiesterase 4D interacting protein |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of PDE4DIP mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:185,293,236...185,490,100
Ensembl chr 2:185,293,214...185,468,379
|
|
G |
Pdss2 |
decaprenyl diphosphate synthase subunit 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of PDSS2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr20:46,709,631...46,938,704
Ensembl chr20:46,709,649...46,938,708
|
|
G |
Phlda1 |
pleckstrin homology-like domain, family A, member 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PHLDA1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:46,967,433...46,969,637
Ensembl chr 7:46,967,409...46,969,861
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions increases expression |
ISO EXP |
AHR affects the reaction [Tetrachlorodibenzodioxin promotes the reaction [PLA2G4A protein results in increased secretion of Arachidonic Acid]]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PLA2G4A mRNA] PLA2G4A protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid] Arachidonic Acid results in increased expression of PLA2G4A mRNA; Arachidonic Acid results in increased expression of PLA2G4A protein |
CTD |
PMID:15878913 PMID:16120751 PMID:19162293 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions |
ISO |
PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Arachidonic Acid] |
CTD |
PMID:9495842 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Pla2g6 |
phospholipase A2 group VI |
multiple interactions |
EXP |
PLA2G6 protein promotes the reaction [2,2',4,6-tetrachlorobiphenyl results in increased secretion of Arachidonic Acid] |
CTD |
PMID:16120751 |
|
NCBI chr 7:110,851,378...110,891,557
Ensembl chr 7:110,851,378...110,891,114
|
|
G |
Plaa |
phospholipase A2, activating protein |
multiple interactions |
ISO |
PLAA protein promotes the reaction [Lipopolysaccharides results in increased abundance of Arachidonic Acid] |
CTD |
PMID:11094054 |
|
NCBI chr 5:109,428,600...109,460,373
Ensembl chr 5:109,428,265...109,460,282
|
|
G |
Plin2 |
perilipin 2 |
increases expression |
ISO EXP |
Arachidonic Acid results in increased expression of PLIN2 mRNA Arachidonic Acid results in increased expression of PLIN2 mRNA; Arachidonic Acid results in increased expression of PLIN2 protein |
CTD |
PMID:16489205 |
|
NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PMAIP1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr18:59,986,020...59,992,434
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pon1 |
paraoxonase 1 |
multiple interactions decreases activity |
ISO |
Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of Paraoxon]; Arachidonic Acid inhibits the reaction [PON1 protein results in increased hydrolysis of phenylacetic acid] Arachidonic Acid results in decreased activity of PON1 protein |
CTD |
PMID:15375178 |
|
NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of PPARA mRNA; Arachidonic Acid results in increased expression of PPARA protein Arachidonic Acid binds to and results in increased activity of PPARA protein |
CTD |
PMID:10403814 PMID:11172467 PMID:15491415 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Ppard |
peroxisome proliferator-activated receptor delta |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PPARD mRNA |
CTD |
PMID:11172467 |
|
NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968
|
|
G |
Pparg |
peroxisome proliferator-activated receptor gamma |
decreases expression increases expression multiple interactions |
ISO EXP |
Arachidonic Acid results in decreased expression of PPARG mRNA; Arachidonic Acid results in decreased expression of PPARG protein Arachidonic Acid results in increased expression of PPARG protein Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in decreased expression of PPARG mRNA] |
CTD |
PMID:11172467 PMID:12604186 PMID:19063610 |
|
NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468
|
|
G |
Ppp1ca |
protein phosphatase 1 catalytic subunit alpha |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of PPP1CA mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 1:201,485,117...201,488,734
Ensembl chr 1:201,485,085...201,497,327
|
|
G |
Prpf4 |
pre-mRNA splicing tri-snRNP complex factor 4 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of PRPF4 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 5:75,859,934...75,873,924
Ensembl chr 5:75,859,924...75,873,919
|
|
G |
Psat1 |
phosphoserine aminotransferase 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PSAT1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 1:213,196,709...213,218,564
Ensembl chr 1:213,196,709...213,218,682
|
|
G |
Ptafr |
platelet-activating factor receptor |
multiple interactions |
EXP |
[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of PTAFR mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of PTAFR mRNA] |
CTD |
PMID:17515866 |
|
NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
increases activity increases response to substance increases metabolic processing multiple interactions |
ISO |
Arachidonic Acid results in increased activity of PTGS1 protein PTGS1 results in increased susceptibility to Arachidonic Acid PTGS1 protein alternative form results in increased metabolism of Arachidonic Acid; PTGS1 protein results in increased metabolism of Arachidonic Acid [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid; [PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of 12-hydroxy-5,8,10-heptadecatrienoic acid]; arzanol inhibits the reaction [[PTGS1 protein results in increased metabolism of Arachidonic Acid] which results in increased chemical synthesis of Thromboxane B2]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS1 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; DuP 697 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; Resveratrol inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; SC 560 inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein]; valerylsalicylate inhibits the reaction [Arachidonic Acid results in increased activity of PTGS1 protein] |
CTD |
PMID:15863457 PMID:16141368 PMID:19751497 PMID:20933508 PMID:21163909 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions increases expression increases metabolic processing increases response to substance increases activity |
ISO EXP |
[[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine] which results in increased abundance of 8-Hydroxy-2'-Deoxyguanosine; [Arachidonic Acid results in increased abundance of Dinoprostone] promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to 3,4-Methylenedioxyamphetamine; [Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine; [lenabasum results in increased expression of PTGS2 mRNA] which results in increased secretion of Arachidonic Acid; [PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA; Arachidonic Acid inhibits the reaction [5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5H)-furanone binds to and results in decreased activity of PTGS2 protein]; Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]; Aspirin inhibits the reaction [[Arachidonic Acid results in increased activity of PTGS2 protein] which results in increased susceptibility to Methamphetamine]; Aspirin inhibits the reaction [Arachidonic Acid results in increased activity of PTGS2 protein]; Dinoprostone promotes the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Flurbiprofen inhibits the reaction [Arachidonic Acid results in increased expression of PTGS2 mRNA]; Ibuprofen inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; nimesulide inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in increased expression of PTGS2 protein PTGS2 results in increased susceptibility to Arachidonic Acid 12-HPETE inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; 2-methoxybenzoic acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; [Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid; [nimesulide results in decreased expression of PTGS2] which results in increased abundance of Arachidonic Acid; [PTGS2 protein results in increased abundance of prostaglandin G2] inhibits the reaction [Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]]; Arachidonic Acid affects the reaction [Tetrachlorodibenzodioxin results in increased expression of PTGS2 mRNA]; Benzoic Acid inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid]; Eugenol inhibits the reaction [[Lipopolysaccharides results in increased expression of and results in increased activity of PTGS2 protein] which results in increased metabolism of Arachidonic Acid]; Sodium Salicylate inhibits the reaction [PTGS2 protein results in increased metabolism of Arachidonic Acid] Arachidonic Acid results in increased expression of PTGS2 mRNA; Arachidonic Acid results in increased expression of PTGS2 protein |
CTD |
PMID:9013627 PMID:9146894 PMID:11112151 PMID:12538810 PMID:12757841 PMID:12821125 PMID:15684433 PMID:15863457 PMID:15878913 PMID:17092368 PMID:17624748 PMID:18297109 PMID:18388244 PMID:18840450 PMID:19063610 PMID:21163909 PMID:22476691 More...
|
|
NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptp4a1 |
protein tyrosine phosphatase 4A1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of PTP4A1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 9:33,214,201...33,245,046
Ensembl chr 9:33,214,208...33,221,964
|
|
G |
Rapgef2 |
Rap guanine nucleotide exchange factor 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of RAPGEF2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:164,207,513...164,322,157
Ensembl chr 2:164,207,513...164,244,247
|
|
G |
Retn |
resistin |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of RETN mRNA |
CTD |
PMID:15949695 |
|
NCBI chr12:1,710,881...1,712,621
Ensembl chr12:1,710,881...1,712,620
|
|
G |
Rps6kb1 |
ribosomal protein S6 kinase B1 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Quercetin results in decreased phosphorylation of RPS6KB1 protein] |
CTD |
PMID:20551291 |
|
NCBI chr10:71,323,777...71,367,908
Ensembl chr10:71,323,777...71,367,908
|
|
G |
Rxra |
retinoid X receptor alpha |
affects binding |
ISO |
Arachidonic Acid binds to RXRA protein |
CTD |
PMID:16258897 |
|
NCBI chr 3:10,989,832...11,076,366
Ensembl chr 3:10,989,832...11,073,712
|
|
G |
Scd |
stearoyl-CoA desaturase |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SCD mRNA |
CTD |
PMID:21457203 |
|
NCBI chr 1:243,269,745...243,282,878
Ensembl chr 1:243,269,747...243,282,562
|
|
G |
Selp |
selectin P |
increases expression multiple interactions |
ISO |
Arachidonic Acid results in increased expression of SELP protein Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]; Glucose inhibits the reaction [Aspirin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein]]; Quercetin inhibits the reaction [Arachidonic Acid results in increased expression of SELP protein] |
CTD |
PMID:17543677 PMID:18413191 PMID:23249183 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Serpinb2 |
serpin family B member 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SERPINB2 mRNA |
CTD |
PMID:18388244 |
|
NCBI chr13:23,537,312...23,551,823
Ensembl chr13:23,541,400...23,550,408
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SKP2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:58,161,226...58,189,293
Ensembl chr 2:58,161,229...58,189,338
|
|
G |
Slc4a2 |
solute carrier family 4 member 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SLC4A2 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 4:10,736,419...10,754,407
Ensembl chr 4:10,736,425...10,752,965
|
|
G |
Slc7a11 |
solute carrier family 7 member 11 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SLC7A11 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SNAI2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr11:86,182,788...86,186,203
Ensembl chr11:86,181,909...86,186,200
|
|
G |
Socs3 |
suppressor of cytokine signaling 3 |
multiple interactions |
ISO |
Arachidonic Acid promotes the reaction [Tetrachlorodibenzodioxin results in increased expression of SOCS3 mRNA] |
CTD |
PMID:19063610 |
|
NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases activity increases activity multiple interactions |
EXP |
Arachidonic Acid results in decreased activity of SOD1 protein Arachidonic Acid results in increased activity of SOD1 protein 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in decreased activity of SOD1 protein] |
CTD |
PMID:16982041 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases activity increases expression |
ISO EXP |
[Arachidonic Acid results in increased abundance of Reactive Oxygen Species] which results in increased expression of SOD2; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Acetylcysteine inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Arachidonic Acid results in increased expression of and results in increased activity of SOD2 protein; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; calphostin C inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Dactinomycin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; Masoprocol inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein]; Phenols inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 mRNA]; pyrrolidine dithiocarbamic acid inhibits the reaction [Arachidonic Acid results in increased expression of SOD2 protein] Arachidonic Acid results in increased activity of SOD2 protein 2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein]; Indomethacin inhibits the reaction [Arachidonic Acid results in increased activity of SOD2 protein] |
CTD |
PMID:12031898 PMID:16982041 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Sox9 |
SRY-box transcription factor 9 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SOX9 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994
|
|
G |
Sparc |
secreted protein acidic and cysteine rich |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SPARC mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396
|
|
G |
Spast |
spastin |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SPAST mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 6:21,055,349...21,106,586
Ensembl chr 6:21,055,349...21,107,954
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of SQSTM1 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673
|
|
G |
Srgap2 |
SLIT-ROBO Rho GTPase activating protein 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SRGAP2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr13:42,745,956...42,967,091
Ensembl chr13:42,745,947...42,967,058
|
|
G |
Srxn1 |
sulfiredoxin 1 |
increases expression |
EXP |
Arachidonic Acid metabolite results in increased expression of SRXN1 mRNA |
CTD |
PMID:27012417 |
|
NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448
|
|
G |
Ssr2 |
signal sequence receptor subunit 2 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of SSR2 mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 2:174,048,291...174,057,043
Ensembl chr 2:174,048,460...174,057,042
|
|
G |
Star |
steroidogenic acute regulatory protein |
increases expression multiple interactions |
EXP |
Arachidonic Acid results in increased expression of STAR protein Arachidonic Acid inhibits the reaction [Dimethoate results in decreased expression of STAR protein] |
CTD |
PMID:22476691 |
|
NCBI chr16:66,267,094...66,274,368
Ensembl chr16:66,264,807...66,271,672
|
|
G |
Stc2 |
stanniocalcin 2 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of STC2 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,250,853...16,262,973
|
|
G |
Stk11 |
serine/threonine kinase 11 |
multiple interactions |
ISO |
STK11 protein affects the reaction [resveratrol results in decreased susceptibility to [Arachidonic Acid co-treated with Iron]] |
CTD |
PMID:19620254 |
|
NCBI chr 7:9,574,553...9,591,315
Ensembl chr 7:9,575,269...9,591,315
|
|
G |
Tfeb |
transcription factor EB |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of TFEB mRNA |
CTD |
PMID:16623957 |
|
NCBI chr 9:13,198,890...13,254,726
Ensembl chr 9:13,198,891...13,254,714
|
|
G |
Tfrc |
transferrin receptor |
multiple interactions increases expression |
EXP |
NGF protein inhibits the reaction [Arachidonic Acid results in increased expression of TFRC protein] |
CTD |
PMID:17551831 |
|
NCBI chr11:68,163,413...68,185,257
Ensembl chr11:68,163,413...68,185,257
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TGFB1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression multiple interactions |
ISO |
Arachidonic Acid results in decreased expression of THRSP mRNA Flurbiprofen inhibits the reaction [Arachidonic Acid results in decreased expression of THRSP mRNA] |
CTD |
PMID:10357836 |
|
NCBI chr 1:151,723,415...151,727,740
Ensembl chr 1:151,723,086...151,728,075
|
|
G |
Timp1 |
TIMP metallopeptidase inhibitor 1 |
multiple interactions |
EXP |
[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA; CYGB protein inhibits the reaction [[ferric nitrilotriacetate co-treated with Arachidonic Acid] results in increased expression of TIMP1 mRNA] |
CTD |
PMID:16581302 |
|
NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664
|
|
G |
Tlr4 |
toll-like receptor 4 |
multiple interactions |
EXP |
[Docosahexaenoic Acids co-treated with Arachidonic Acid] affects the expression of TLR4 mRNA; Arachidonic Acid inhibits the reaction [1-O-hexadecyl-2-N-methylcarbamylphosphatidylcholine results in increased expression of TLR4 mRNA] |
CTD |
PMID:17515866 |
|
NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases abundance increases secretion |
ISO |
Arachidonic Acid inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased secretion of Arachidonic Acid] TNF protein results in increased abundance of Arachidonic Acid Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]; TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]] |
CTD |
PMID:1515551 PMID:10588948 PMID:15684433 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfrsf12a |
TNF receptor superfamily member 12A |
increases expression |
ISO |
Arachidonic Acid results in increased expression of TNFRSF12A mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:12,707,077...12,709,071
Ensembl chr10:12,689,890...12,709,045
|
|
G |
Tnfrsf1a |
TNF receptor superfamily member 1A |
multiple interactions |
ISO |
TNFRSF1A protein affects the reaction [Butylated Hydroxyanisole inhibits the reaction [TNF protein results in increased abundance of Arachidonic Acid]] |
CTD |
PMID:10588948 |
|
NCBI chr 4:158,150,815...158,163,592
Ensembl chr 4:158,150,820...158,163,591
|
|
G |
Tns3 |
tensin 3 |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of TNS3 mRNA |
CTD |
PMID:16704987 |
|
NCBI chr14:83,173,649...83,405,671
Ensembl chr14:83,173,649...83,405,998
|
|
G |
Top2a |
DNA topoisomerase II alpha |
decreases expression |
ISO |
Arachidonic Acid results in decreased expression of TOP2A mRNA |
CTD |
PMID:16704987 |
|
NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
[TP53 protein mutant form results in increased susceptibility to Niclosamide] which results in increased abundance of Arachidonic Acid [TP53 protein results in increased expression of ALOX12B mRNA] which results in increased metabolism of Arachidonic Acid; [TP53 protein results in increased expression of ALOX5 mRNA] which results in increased metabolism of Arachidonic Acid |
CTD |
PMID:30258081 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Trpa1 |
transient receptor potential cation channel, subfamily A, member 1 |
increases activity multiple interactions |
ISO |
Arachidonic Acid results in increased activity of TRPA1 protein Ruthenium Red inhibits the reaction [Arachidonic Acid results in increased activity of TRPA1 protein] |
CTD |
PMID:15046718 |
|
NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570
|
|
G |
Trpc4 |
transient receptor potential cation channel, subfamily C, member 4 |
multiple interactions |
ISO |
TRPC4 protein affects the reaction [Arachidonic Acid results in increased transport of Calcium] |
CTD |
PMID:11830588 |
|
NCBI chr 2:138,307,676...138,476,856
Ensembl chr 2:138,308,084...138,476,768
|
|
G |
Trpv1 |
transient receptor potential cation channel, subfamily V, member 1 |
multiple interactions |
EXP |
[Arachidonic Acid co-treated with Phorbol 12,13-Dibutyrate] results in increased activity of TRPV1 protein |
CTD |
PMID:17038422 |
|
NCBI chr10:57,851,428...57,876,513
Ensembl chr10:57,851,428...57,876,513
|
|
G |
Trpv4 |
transient receptor potential cation channel, subfamily V, member 4 |
increases activity |
ISO |
Arachidonic Acid results in increased activity of TRPV4 protein |
CTD |
PMID:20956320 |
|
NCBI chr12:41,938,533...41,977,517
Ensembl chr12:41,938,560...41,977,517
|
|
G |
Ugt1a1 |
UDP glucuronosyltransferase family 1 member A1 |
increases glucuronidation |
ISO |
UGT1A1 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a2 |
UDP glucuronosyltransferase 1 family, polypeptide A2 |
increases glucuronidation |
ISO |
UGT1A3 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a5 |
UDP glucuronosyltransferase family 1 member A5 |
increases glucuronidation |
ISO |
UGT1A4 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,762,250...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt1a9 |
UDP glucuronosyltransferase family 1 member A9 |
increases glucuronidation |
ISO |
UGT1A9 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465
|
|
G |
Ugt2b7 |
UDP glucuronosyltransferase family 2 member B7 |
increases glucuronidation |
ISO |
UGT2B7 protein results in increased glucuronidation of Arachidonic Acid |
CTD |
PMID:15231852 |
|
NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions increases expression |
ISO |
[PTGS2 co-treated with Arachidonic Acid] results in increased expression of VEGFA [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein; [Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK1 protein]; CYP2C23 mRNA promotes the reaction [[Arachidonic Acid co-treated with VEGFA protein] results in increased phosphorylation of MAPK3 protein] Arachidonic Acid results in increased expression of VEGFA mRNA |
CTD |
PMID:12821125 PMID:18388244 PMID:19464254 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Ywhaz |
tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, zeta |
increases expression |
ISO |
Arachidonic Acid results in increased expression of YWHAZ mRNA |
CTD |
PMID:16704987 |
|
NCBI chr 7:67,941,353...67,963,651
Ensembl chr 7:67,940,017...67,963,668
|
|
G |
Zfp36 |
zinc finger protein 36 |
increases expression |
ISO |
Arachidonic Acid results in increased expression of ZFP36 mRNA |
CTD |
PMID:8764118 |
|
NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:83,669,084...83,671,564
|
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions |
ISO |
arachidonyl-coenzyme A binds to and results in increased activity of PPARA protein |
CTD |
PMID:11139385 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
|
G |
Agrp |
agouti related neuropeptide |
decreases expression |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of AGRP mRNA |
CTD |
PMID:26468265 |
|
NCBI chr19:33,447,992...33,481,602
Ensembl chr19:33,447,992...33,449,584
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation |
ISO |
arachidonyl-2-chloroethylamide results in decreased phosphorylation of AKT1 protein |
CTD |
PMID:26847930 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Angpt1 |
angiopoietin 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT1 protein] |
CTD |
PMID:26467187 |
|
NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:73,531,486...73,784,067
|
|
G |
Angpt2 |
angiopoietin 2 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of ANGPT2 protein] |
CTD |
PMID:26467187 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Avp |
arginine vasopressin |
multiple interactions |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of AVP mRNA] |
CTD |
PMID:26468265 |
|
NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Streptozocin co-treated with arachidonyl-2-chloroethylamide] results in increased expression of BCL2 protein arachidonyl-2-chloroethylamide results in increased expression of BCL2 protein |
CTD |
PMID:30607903 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Cartpt |
CART prepropeptide |
decreases expression multiple interactions |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of CARTPT mRNA [arachidonyl-2-chloroethylamide co-treated with Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of CARTPT mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 2:31,255,098...31,257,452
Ensembl chr 2:31,255,098...31,290,713
|
|
G |
Casp3 |
caspase 3 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP3 protein] |
CTD |
PMID:31256211 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp9 |
caspase 9 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of CASP9 protein] |
CTD |
PMID:31256211 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr10:68,466,394...68,468,229
Ensembl chr10:68,452,052...68,468,231
|
|
G |
Cd86 |
CD86 molecule |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cnr1 |
cannabinoid receptor 1 |
multiple interactions |
EXP ISO |
CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CCL4 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of CD86 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein] |
CTD |
PMID:12734338 PMID:27455076 PMID:29033935 |
|
NCBI chr 5:48,408,543...48,436,099
Ensembl chr 5:48,408,574...48,435,099
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
multiple interactions increases expression |
ISO |
ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA] arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA; arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein |
CTD |
PMID:31912162 |
|
NCBI chr 1:206,890,635...206,947,332
Ensembl chr 1:206,890,638...206,947,232
|
|
G |
Daglb |
diacylglycerol lipase, beta |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA] |
CTD |
PMID:31912162 |
|
NCBI chr12:11,059,732...11,102,170
Ensembl chr12:11,059,732...11,102,154
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased expression of DDIT3 protein] |
CTD |
PMID:31256211 |
|
NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201
|
|
G |
Drd2 |
dopamine receptor D2 |
decreases expression |
EXP |
arachidonyl-2-chloroethylamide results in decreased expression of DRD2 mRNA |
CTD |
PMID:22791651 |
|
NCBI chr 8:49,708,927...49,772,876
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Esrrg |
estrogen-related receptor gamma |
increases expression multiple interactions |
ISO EXP |
arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA; arachidonyl-2-chloroethylamide results in increased expression of ESRRG protein ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLA promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to DAGLB promoter]; arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of ESRRG mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA protein]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of DAGLB]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] |
CTD |
PMID:27455076 PMID:30019168 PMID:31912162 |
|
NCBI chr13:99,167,656...99,788,016
Ensembl chr13:99,564,669...99,783,397
|
|
G |
Fga |
fibrinogen alpha chain |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGA mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528
|
|
G |
Fgb |
fibrinogen beta chain |
multiple interactions increases expression |
ISO |
GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGB mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,394,901...168,402,863
Ensembl chr 2:168,394,916...168,405,979
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression increases secretion multiple interactions |
ISO EXP |
arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein arachidonyl-2-chloroethylamide promotes the reaction [ESRRG protein binds to FGF21 promoter]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased secretion of FGF21 protein] ESRRG protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA]; GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA] arachidonyl-2-chloroethylamide results in increased expression of FGF21 mRNA; arachidonyl-2-chloroethylamide results in increased expression of FGF21 protein |
CTD |
PMID:27455076 |
|
NCBI chr 1:96,083,360...96,084,911
Ensembl chr 1:96,083,441...96,090,454
|
|
G |
Fgg |
fibrinogen gamma chain |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA GSK5182 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of FGG mRNA] |
CTD |
PMID:30019168 |
|
NCBI chr 2:168,354,880...168,362,325
Ensembl chr 2:168,355,013...168,362,322
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions decreases phosphorylation |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] arachidonyl-2-chloroethylamide results in decreased phosphorylation of FOXO1 protein |
CTD |
PMID:26847930 |
|
NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]] |
CTD |
PMID:26847930 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein] |
CTD |
PMID:26671069 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Hcrt |
hypocretin neuropeptide precursor |
increases expression |
EXP |
arachidonyl-2-chloroethylamide results in increased expression of HCRT mRNA |
CTD |
PMID:26468265 |
|
NCBI chr10:85,689,979...85,691,214
Ensembl chr10:85,689,465...85,691,210
|
|
G |
Il6 |
interleukin 6 |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of IL6 mRNA] |
CTD |
PMID:29033935 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Ins1 |
insulin 1 |
multiple interactions |
ISO |
[arachidonyl-2-chloroethylamide co-treated with Glucose] results in increased secretion of INS1 protein; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein results in increased activity of GSR protein]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of G6PC1 protein]]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26671069 PMID:26847930 PMID:30761839 |
|
NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions increases phosphorylation |
ISO EXP |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK1 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK1 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK1 protein] |
CTD |
PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions increases phosphorylation |
ISO EXP |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein]; arachidonyl-2-chloroethylamide promotes the reaction [Streptozocin results in increased phosphorylation of MAPK3 protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of MAPK3 protein] arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased phosphorylation of and results in increased activity of MAPK3 protein] |
CTD |
PMID:12734338 PMID:19477951 PMID:26467187 PMID:29033935 PMID:30607903 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mpo |
myeloperoxidase |
multiple interactions increases activity |
ISO |
Acetylcysteine inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein]; SB 203580 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of MPO protein] |
CTD |
PMID:32033504 |
|
NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of NOS2 protein] |
CTD |
PMID:29033935 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nrf1 |
nuclear respiratory factor 1 |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of NRF1 mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328
|
|
G |
Olig2 |
oligodendrocyte transcription factor 2 |
increases expression |
EXP |
arachidonyl-2-chloroethylamide results in increased expression of OLIG2 protein |
CTD |
PMID:17880390 |
|
NCBI chr11:30,475,510...30,478,886
Ensembl chr11:30,475,398...30,480,152
|
|
G |
Oxt |
oxytocin/neurophysin I prepropeptide |
multiple interactions |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of OXT mRNA]; arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased secretion of OXT protein] |
CTD |
PMID:26468265 |
|
NCBI chr 3:117,782,650...117,783,490
Ensembl chr 3:117,782,650...117,783,490
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased cleavage of PARP1 protein] |
CTD |
PMID:31256211 |
|
NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404
|
|
G |
Pck1 |
phosphoenolpyruvate carboxykinase 1 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]; FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [INS1 protein inhibits the reaction [[Cyclic AMP co-treated with Dexamethasone] results in increased expression of PEPCK protein]]] |
CTD |
PMID:26847930 |
|
NCBI chr 3:161,930,256...161,936,205
Ensembl chr 3:161,930,256...161,936,191
|
|
G |
Pmch |
pro-melanin-concentrating hormone |
multiple interactions increases expression |
EXP |
arachidonyl-2-chloroethylamide promotes the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of PMCH mRNA] arachidonyl-2-chloroethylamide results in increased expression of PMCH mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 7:22,511,934...22,513,250
Ensembl chr 7:22,511,934...22,513,250
|
|
G |
Pomc |
proopiomelanocortin |
multiple interactions decreases expression |
EXP |
arachidonyl-2-chloroethylamide inhibits the reaction [[Water deficiency co-treated with Sodium Chloride, Dietary deficiency] results in increased expression of POMC mRNA] arachidonyl-2-chloroethylamide results in decreased expression of POMC mRNA |
CTD |
PMID:26468265 |
|
NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions decreases expression |
ISO |
FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of PPARGC1A mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions affects localization |
ISO |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide affects the localization of RELA protein] |
CTD |
PMID:29033935 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Rhoa |
ras homolog family member A |
multiple interactions increases activity |
ISO |
AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased activity of RHOA protein] |
CTD |
PMID:29033935 |
|
NCBI chr 8:108,991,926...109,025,746
Ensembl chr 8:108,991,954...109,025,746
|
|
G |
Tfam |
transcription factor A, mitochondrial |
decreases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA FOXO1 protein affects the reaction [arachidonyl-2-chloroethylamide results in decreased expression of TFAM mRNA] |
CTD |
PMID:26847930 |
|
NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA; arachidonyl-2-chloroethylamide results in increased expression of TNF protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; AM 281 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; CNR1 protein affects the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Pertussis Toxin inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF mRNA]; Y 27632 inhibits the reaction [arachidonyl-2-chloroethylamide results in increased expression of TNF protein] |
CTD |
PMID:29033935 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
arachidonyl-2-chloroethylamide inhibits the reaction [Cisplatin results in increased phosphorylation of TRP53 protein] |
CTD |
PMID:31256211 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFA protein] |
CTD |
PMID:26467187 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vegfc |
vascular endothelial growth factor C |
multiple interactions |
ISO |
AM 251 inhibits the reaction [arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein]]; arachidonyl-2-chloroethylamide inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased secretion of VEGFC protein] |
CTD |
PMID:26467187 |
|
NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848
|
|
|
G |
Lipc |
lipase C, hepatic type |
multiple interactions |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate |
CTD |
PMID:24777581 |
|
NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464
|
|
G |
Lipg |
lipase G, endothelial type |
multiple interactions decreases abundance |
ISO |
[LIPC gene mutant form co-treated with LIPG gene mutant form] results in increased abundance of cholesteryl arachidonate LIPG gene mutant form results in decreased abundance of cholesteryl arachidonate |
CTD |
PMID:24777581 |
|
NCBI chr18:68,514,923...68,536,105
Ensembl chr18:68,514,923...68,536,260
|
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases chemical synthesis |
ISO |
ALOX5 protein results in increased chemical synthesis of Leukotriene A4 |
CTD |
PMID:18295198 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Lta4h |
leukotriene A4 hydrolase |
multiple interactions increases hydrolysis |
ISO |
cyclohexene inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; Oxygen inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4]; propanethiol inhibits the reaction [LTA4H protein results in increased hydrolysis of Leukotriene A4] |
CTD |
PMID:2827578 |
|
NCBI chr 7:27,969,796...28,001,600
Ensembl chr 7:27,969,789...28,001,600
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Leukotriene A4 results in decreased activity of MGST1 protein |
CTD |
PMID:9890956 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
ISO |
Leukotriene B4 results in increased expression of ACTA2 protein Leukotriene B4 results in increased expression of ACTA2 mRNA |
CTD |
PMID:27697457 PMID:30818366 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
EXP |
AHR mRNA promotes the reaction [Tetrachlorodibenzodioxin results in increased chemical synthesis of Leukotriene B4] |
CTD |
PMID:28487374 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Leukotriene B4 inhibits the reaction [isoliquiritigenin results in decreased activity of AKT1 protein] |
CTD |
PMID:23747687 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases secretion increases chemical synthesis multiple interactions |
ISO EXP |
ALOX5 protein results in increased secretion of Leukotriene B4 ALOX5 protein results in increased chemical synthesis of Leukotriene B4 [benoxaprofen results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Hydrogen Peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of Leukotriene B4; [Masoprocol results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [RS 43179 results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [Tamoxifen results in increased expression of ALOX5 protein] which results in increased abundance of Leukotriene B4; [tenidap results in decreased activity of ALOX5 protein] which results in decreased chemical synthesis of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]; ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]; kaempferol inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Luteolin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; quercetin 3'-sulfate inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; quercetin 3-O-glucuronide inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Quercetin inhibits the reaction [ALOX5 protein results in increased chemical synthesis of Leukotriene B4]; Resveratrol inhibits the reaction [[Hydrogen Peroxide results in increased activity of ALOX5 protein] which results in increased chemical synthesis of Leukotriene B4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [lipopolysaccharide, E. coli O26-B6 results in increased abundance of Leukotriene B4]]; zileuton inhibits the reaction [ALOX5 protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]] [[A 78773 co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [[CMI 392 co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [[zileuton co-treated with Calcimycin] results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] which results in increased abundance of Leukotriene B4; [lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [tepoxalin results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [troglitazone results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Calcimycin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [Indomethacin results in increased abundance of Leukotriene B4]; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [CXCL8 protein results in increased abundance of Leukotriene B4]; tetrakis(4-benzoic acid)porphyrin inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene B4; ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene B4]] |
CTD |
PMID:1781415 PMID:2849922 PMID:8058773 PMID:9223651 PMID:9445378 PMID:9593866 PMID:9609743 PMID:9742967 PMID:10491155 PMID:10694244 PMID:11286996 PMID:11325678 PMID:11529688 PMID:12388339 PMID:12794006 PMID:15501964 PMID:18096136 PMID:18475545 More...
|
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]; L 655238 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]]; MK-886 inhibits the reaction [ALOX5AP protein results in increased susceptibility to [Histamine results in increased abundance of Leukotriene B4]] |
CTD |
PMID:9609743 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression multiple interactions |
ISO |
Leukotriene B4 results in decreased expression of BAX mRNA; Leukotriene B4 results in decreased expression of BAX protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of BAX protein]; wortmannin inhibits the reaction [Leukotriene B4 results in increased expression of BAX protein] |
CTD |
PMID:15970427 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
C5 |
complement C5 |
multiple interactions increases abundance |
ISO |
MK 0591 inhibits the reaction [C5 protein results in increased abundance of Leukotriene B4] |
CTD |
PMID:10477617 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases abundance multiple interactions |
ISO |
CCL12 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [CCL12 protein results in increased abundance of Leukotriene B4] |
CTD |
PMID:12388339 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression multiple interactions increases abundance |
ISO |
Leukotriene B4 results in increased expression of CCL2 protein zileuton inhibits the reaction [CCL2 protein results in increased abundance of Leukotriene B4] |
CTD |
PMID:12388339 PMID:19880577 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
multiple interactions |
EXP |
[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4; Dexamethasone inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4]; Masoprocol inhibits the reaction [[Calcimycin co-treated with CCL5 protein] results in increased secretion of Leukotriene B4] |
CTD |
PMID:18083043 |
|
NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Col1a1 |
collagen type I alpha 1 chain |
increases expression |
ISO |
Leukotriene B4 results in increased expression of COL1A1 mRNA |
CTD |
PMID:30818366 |
|
NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases secretion |
ISO |
Leukotriene B4 results in increased secretion of CSF2 protein |
CTD |
PMID:15136573 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases abundance multiple interactions |
ISO |
CXCL1 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [CXCL1 protein results in increased abundance of Leukotriene B4] |
CTD |
PMID:12388339 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions |
ISO |
[LY 171883 binds to and results in decreased activity of CYSLTR1 protein] which results in decreased abundance of Leukotriene B4 |
CTD |
PMID:8014878 |
|
NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Fgf2 |
fibroblast growth factor 2 |
increases expression |
ISO |
Leukotriene B4 results in increased expression of FGF2 mRNA |
CTD |
PMID:30818366 |
|
NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Leukotriene B4 inhibits the reaction [Zymosan results in increased expression of HMOX1 protein] |
CTD |
PMID:11454666 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
multiple interactions decreases expression decreases activity |
ISO |
[2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; [Masoprocol co-treated with Leukotriene B4] results in decreased expression of HSD11B2 protein; Leukotriene B4 inhibits the reaction [2,3,5-trimethyl-6-(12-hydroxy-5,10-dodecadiynyl)-1,4-benzoquinone results in increased activity of HSD11B2 protein]; Leukotriene B4 inhibits the reaction [Masoprocol results in increased activity of HSD11B2 protein] Leukotriene B4 results in decreased expression of HSD11B2 mRNA Leukotriene B4 results in decreased activity of HSD11B2 protein |
CTD |
PMID:10377029 PMID:18032417 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4; Mangifera indica extract inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4]; mangiferin inhibits the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased abundance of Leukotriene B4] |
CTD |
PMID:15177302 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il10 |
interleukin 10 |
multiple interactions |
ISO |
Leukotriene B4 promotes the reaction [Lipopolysaccharides results in increased secretion of IL10 protein] |
CTD |
PMID:16313356 |
|
NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
Leukotriene B4 inhibits the reaction [Lipopolysaccharides results in increased secretion of IL12B protein] |
CTD |
PMID:16313356 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
increases abundance multiple interactions |
EXP |
IL13 protein results in increased abundance of Leukotriene B4 zileuton inhibits the reaction [IL13 protein results in increased abundance of Leukotriene B4] |
CTD |
PMID:12654629 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases abundance |
ISO |
resveratrol inhibits the reaction [IL1B protein results in increased abundance of Leukotriene B4] |
CTD |
PMID:18759268 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il4 |
interleukin 4 |
multiple interactions |
ISO |
IL4 protein inhibits the reaction [Calcimycin results in increased metabolism of Leukotriene B4]; IL4 protein inhibits the reaction [Zymosan affects the metabolism of Leukotriene B4] |
CTD |
PMID:11861792 |
|
NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions increases expression |
ISO |
Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]; LY 255283 analog inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 255283 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 293111 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]] LTB4 increases expression of ITGAM protein on neutrophils and monocytes |
CTD RGD |
PMID:7473568 PMID:18064325 |
RGD:329901666 |
NCBI chr 1:182,659,047...182,709,501
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb2 |
integrin subunit beta 2 |
increases expression multiple interactions |
EXP ISO |
Leukotriene B4 results in increased expression of ITGB2 protein Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]; LY 255283 analog inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 255283 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]]; LY 293111 inhibits the reaction [Leukotriene B4 results in increased expression of [ITGAM protein binds to ITGB2 protein]] |
CTD |
PMID:7473568 PMID:14716214 |
|
NCBI chr20:11,061,394...11,097,656
Ensembl chr20:11,061,430...11,097,600
|
|
G |
Lta4h |
leukotriene A4 hydrolase |
multiple interactions increases chemical synthesis |
ISO |
1-(4-(benzothiazol-2-yloxy)benzyl)piperidine-4-carboxylic acid inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; cyclohexene inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; Oxygen inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; Piperonyl Butoxide inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4]; propanethiol inhibits the reaction [LTA4H protein results in increased chemical synthesis of Leukotriene B4] |
CTD |
PMID:2827578 PMID:17371808 |
|
NCBI chr 7:27,969,796...28,001,600
Ensembl chr 7:27,969,789...28,001,600
|
|
G |
Ltb4r |
leukotriene B4 receptor |
multiple interactions affects response to substance affects binding |
ISO |
[SC 41930 binds to and results in decreased activity of LTB4R protein] which results in decreased abundance of Leukotriene B4; Leukotriene B4 binds to and affects the activity of LTB4R1 protein Leukotriene B4 binds to and results in increased activity of LTB4R protein; LY 255283 analog inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein]; LY 255283 inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein]; LY 293111 inhibits the reaction [Leukotriene B4 binds to and results in increased activity of LTB4R protein] LTB4R1 protein affects the susceptibility to Leukotriene B4 Leukotriene B4 analog binds to LTB4R1 protein |
CTD |
PMID:7473568 PMID:8014878 PMID:10934232 PMID:11006272 |
|
NCBI chr15:29,263,199...29,265,716
|
|
G |
Ltb4r2 |
leukotriene B4 receptor 2 |
affects binding |
ISO |
Leukotriene B4 binds to LTB4R2 protein |
CTD |
PMID:11006272 |
|
NCBI chr15:29,258,712...29,260,531
Ensembl chr15:29,259,240...29,260,316
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Leukotriene B4 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19837106 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Leukotriene B4 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19837106 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
increases expression multiple interactions |
ISO |
Leukotriene B4 results in increased expression of MCL1 mRNA; Leukotriene B4 results in increased expression of MCL1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of MCL1 protein]; wortmannin inhibits the reaction [Leukotriene B4 results in increased expression of MCL1 protein] |
CTD |
PMID:15970427 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Leukotriene B4 results in decreased activity of MGST1 protein |
CTD |
PMID:9890956 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene B4 results in increased expression of MMP9 protein] |
CTD |
PMID:19837106 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
increases expression |
EXP |
Leukotriene B4 results in increased expression of MUC5AC protein |
CTD |
PMID:12654629 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Leukotriene B4 inhibits the reaction [[Zymosan results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites] |
CTD |
PMID:11454666 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pla2g4a |
phospholipase A2 group 4A |
multiple interactions |
ISO |
PLA2G4A protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased metabolism of Leukotriene B4]; PLA2G4A protein promotes the reaction [Zymosan analog results in increased metabolism of Leukotriene B4] |
CTD |
PMID:11741884 |
|
NCBI chr13:61,877,818...62,022,261
Ensembl chr13:61,877,813...62,022,266
|
|
G |
Ppara |
peroxisome proliferator activated receptor alpha |
multiple interactions affects binding |
ISO |
Leukotriene B4 binds to and results in increased activity of PPARA protein Leukotriene B4 binds to PPARA protein |
CTD |
PMID:10403814 PMID:12009843 PMID:15491415 |
|
NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346
|
|
G |
Sell |
selectin L |
increases expression |
EXP |
Leukotriene B4 results in increased expression of SELL protein |
CTD |
PMID:14716214 |
|
NCBI chr13:76,416,969...76,436,444
Ensembl chr13:76,416,915...76,436,456
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
increases expression |
ISO |
Leukotriene B4 results in increased expression of TGFB1 mRNA |
CTD |
PMID:30818366 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
affects transport |
ISO |
ABCA8 protein affects the transport of Leukotriene C4 |
CTD |
PMID:12379217 |
|
NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
affects transport multiple interactions increases uptake decreases transport affects binding |
ISO |
ABCC1 protein affects the transport of Leukotriene C4 [Nimustine results in increased expression of ABCC1 protein] which results in increased transport of Leukotriene C4; Adenosine Triphosphate promotes the reaction [ABCC1 protein affects the transport of Leukotriene C4]; Apigenin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Bilirubin inhibits the reaction [ABCC1 protein affects the transport of Leukotriene C4]; estradiol-17 beta-glucuronide inhibits the reaction [ABCC1 protein affects the transport of Leukotriene C4]; Genistein affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Glutathione Disulfide promotes the reaction [Leukotriene C4 analog binds to ABCC1 protein]; Glutathione promotes the reaction [Apigenin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; Glutathione promotes the reaction [Genistein affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; Glutathione promotes the reaction [naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]]; kaempferol inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; myricetin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; naringenin affects the reaction [ABCC1 protein results in increased uptake of Leukotriene C4]; Quercetin inhibits the reaction [ABCC1 protein results in increased uptake of Leukotriene C4] ABCC1 protein mutant form results in decreased transport of Leukotriene C4 |
CTD |
PMID:9393752 PMID:11278867 PMID:11306701 PMID:15245331 PMID:15355964 PMID:15459206 PMID:15628876 PMID:18336795 More...
|
|
NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases transport multiple interactions affects transport |
EXP ISO |
ABCC2 protein modified form results in increased transport of Leukotriene C4 verlukast inhibits the reaction [ABCC2 protein results in increased transport of Leukotriene C4] ABCC2 protein affects the transport of Leukotriene C4 |
CTD |
PMID:9430713 PMID:11500505 PMID:12388192 PMID:12395335 PMID:15507541 PMID:15904671 PMID:27676153 More...
|
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
verlukast inhibits the reaction [ABCC3 protein results in increased transport of Leukotriene C4] |
CTD |
PMID:27676153 |
|
NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
affects transport |
ISO |
ABCC6 protein affects the transport of Leukotriene C4 |
CTD |
PMID:11880368 |
|
NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO EXP |
[zileuton results in decreased activity of ALOX5 protein] inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4]; [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene C4 [Calcimycin results in increased activity of and results in increased localization of ALOX5 protein] which results in increased abundance of Leukotriene C4 ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene C4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene C4]] |
CTD |
PMID:9445378 PMID:9495842 PMID:10764316 PMID:12794006 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Alox5ap |
arachidonate 5-lipoxygenase activating protein |
multiple interactions |
ISO |
[2-(4-(quinolin-2-yl-methoxy)phenyl)-2-cyclopentylacetic acid results in decreased activity of ALOX5AP protein] which results in decreased abundance of Leukotriene C4; [MK-886 results in decreased activity of ALOX5AP protein] which results in decreased abundance of Leukotriene C4 |
CTD |
PMID:9113110 |
|
NCBI chr12:5,748,941...5,772,986
Ensembl chr12:5,748,944...5,772,986
|
|
G |
Ambp |
alpha-1-microglobulin/bikunin precursor |
decreases secretion |
EXP |
AMBP protein results in decreased secretion of Leukotriene C4 |
CTD |
PMID:9579392 |
|
NCBI chr 5:76,568,094...76,578,416
Ensembl chr 5:76,568,094...76,578,331
|
|
G |
Ccl12 |
C-C motif chemokine ligand 12 |
increases expression |
ISO |
Leukotriene C4 results in increased expression of CCL12 mRNA |
CTD |
PMID:12388339 |
|
NCBI chr10:67,070,230...67,071,780
Ensembl chr10:67,070,230...67,071,780
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO |
Leukotriene C4 results in increased expression of CCL2 mRNA |
CTD |
PMID:12388339 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Clec7a |
C-type lectin domain containing 7A |
multiple interactions |
ISO |
CLEC7A protein promotes the reaction [Peptidoglycan results in increased metabolism of Leukotriene C4]; CLEC7A protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4] |
CTD |
PMID:17030235 |
|
NCBI chr 4:162,902,731...162,913,931
Ensembl chr 4:162,902,732...162,913,897
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
increases expression |
ISO |
Leukotriene C4 results in increased expression of CXCL1 mRNA |
CTD |
PMID:12388339 |
|
NCBI chr14:17,287,727...17,289,451
Ensembl chr14:17,270,146...17,289,511
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions affects binding |
ISO |
[Leukotriene C4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; CGP 57698 inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; Leukotriene C4 binds to and results in increased activity of CYSLTR1 protein; MEN91507 inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; pobilukast inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene C4 binds to CYSLTR1 protein] CYSLTR1 protein binds to and affects the susceptibility to Leukotriene C4; Leukotriene C4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein] |
CTD |
PMID:8384568 PMID:10391245 PMID:10462554 PMID:10825389 PMID:11705452 PMID:11932261 PMID:11996896 PMID:12853847 More...
|
|
NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Cysltr2 |
cysteinyl leukotriene receptor 2 |
multiple interactions increases activity |
ISO |
[Leukotriene C4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene C4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; Leukotriene C4 binds to and results in increased activity of CYSLTR2 protein |
CTD |
PMID:10851239 PMID:11093801 |
|
NCBI chr15:48,189,476...48,228,750
Ensembl chr15:48,189,073...48,304,136
|
|
G |
Edn1 |
endothelin 1 |
increases expression multiple interactions |
ISO |
Leukotriene C4 results in increased expression of EDN1 mRNA; Leukotriene C4 results in increased expression of EDN1 protein zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 mRNA]; zafirlukast inhibits the reaction [Leukotriene C4 results in increased expression of EDN1 protein] |
CTD |
PMID:11372388 |
|
NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885
|
|
G |
Egfr |
epidermal growth factor receptor |
increases expression |
ISO |
Leukotriene C4 results in increased expression of EGFR mRNA |
CTD |
PMID:12388339 |
|
NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382
|
|
G |
Ggt5 |
gamma-glutamyltransferase 5 |
multiple interactions |
ISO |
[Beclomethasone results in increased activity of GGT5 protein] which results in increased metabolism of Leukotriene C4; [Fluticasone results in increased activity of GGT5 protein] which results in increased metabolism of Leukotriene C4 |
CTD |
PMID:11447392 |
|
NCBI chr20:13,043,255...13,071,523
Ensembl chr20:13,043,257...13,071,450
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Leukotriene C4 results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Hmox1 |
heme oxygenase 1 |
multiple interactions |
ISO |
Leukotriene C4 inhibits the reaction [Zymosan results in increased expression of HMOX1 protein] |
CTD |
PMID:11454666 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Il13 |
interleukin 13 |
increases expression multiple interactions increases abundance |
ISO EXP |
Leukotriene C4 results in increased expression of IL13 mRNA [IL13 protein results in increased abundance of Leukotriene C4] which results in increased secretion of MUC5AC protein |
CTD |
PMID:12388339 PMID:12654629 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il5 |
interleukin 5 |
increases secretion |
ISO |
IL5 protein results in increased secretion of Leukotriene C4 |
CTD |
PMID:9378992 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Ltc4s |
leukotriene C4 synthase |
affects chemical synthesis |
ISO |
LTC4S protein affects the chemical synthesis of Leukotriene C4 |
CTD |
PMID:10666225 |
|
NCBI chr10:34,560,476...34,562,790
Ensembl chr10:34,560,360...34,562,651
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Leukotriene C4 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19837106 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Leukotriene C4 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19837106 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
multiple interactions |
EXP |
Leukotriene C4 binds to and results in decreased activity of MGST1 protein; Leukotriene C4 inhibits the reaction [Glutathione binds to and results in increased activity of MGST1 protein] |
CTD |
PMID:9890956 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene C4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene C4 results in increased expression of MMP9 protein] |
CTD |
PMID:19837106 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
increases expression multiple interactions |
EXP |
Leukotriene C4 results in increased expression of MUC5AC mRNA; Leukotriene C4 results in increased expression of MUC5AC protein [IL13 protein results in increased abundance of Leukotriene C4] which results in increased secretion of MUC5AC protein |
CTD |
PMID:12654629 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
Leukotriene C4 inhibits the reaction [[Zymosan results in increased expression of NOS2 protein] which results in increased chemical synthesis of Nitrites] |
CTD |
PMID:11454666 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Pla2g5 |
phospholipase A2, group V |
multiple interactions |
ISO |
PLA2G5 protein promotes the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased abundance of Leukotriene C4] PLA2G5 protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4] |
CTD |
PMID:9495842 PMID:14761945 |
|
NCBI chr 5:151,041,339...151,109,433
Ensembl chr 5:151,041,340...151,062,658
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased abundance of Leukotriene C4] |
CTD |
PMID:25432964 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Ralbp1 |
ralA binding protein 1 |
multiple interactions affects transport |
ISO |
Adenosine Triphosphate promotes the reaction [RALBP1 protein affects the transport of Leukotriene C4]; Colchicine inhibits the reaction [RALBP1 protein affects the transport of Leukotriene C4] |
CTD |
PMID:15386349 |
|
NCBI chr 9:105,456,425...105,493,235
Ensembl chr 9:105,456,425...105,492,707
|
|
G |
Selp |
selectin P |
increases expression |
ISO |
Leukotriene C4 results in increased expression of SELP protein |
CTD |
PMID:9152370 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Syk |
spleen associated tyrosine kinase |
multiple interactions |
ISO |
SYK protein promotes the reaction [Peptidoglycan results in increased metabolism of Leukotriene C4]; SYK protein promotes the reaction [Zymosan results in increased metabolism of Leukotriene C4] |
CTD |
PMID:17030235 |
|
NCBI chr17:12,604,615...12,678,437
Ensembl chr17:12,604,619...12,661,410
|
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
increases abundance multiple interactions |
ISO |
ALOX5 protein results in increased abundance of Leukotriene D4 ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene D4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene D4]] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene D4 |
CTD |
PMID:10764316 PMID:12629151 PMID:12794006 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Arrb1 |
arrestin, beta 1 |
multiple interactions |
ISO |
Leukotriene D4 promotes the reaction [CYSLTR2 protein binds to ARRB1 protein] |
CTD |
PMID:33288675 |
|
NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061
|
|
G |
Arrb2 |
arrestin, beta 2 |
multiple interactions |
ISO |
Leukotriene D4 promotes the reaction [CYSLTR2 protein binds to ARRB2 protein] |
CTD |
PMID:33288675 |
|
NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850
|
|
G |
Csf2 |
colony stimulating factor 2 |
multiple interactions |
ISO |
Leukotriene D4 promotes the reaction [CSF2 protein results in increased expression of TGFB1 protein] |
CTD |
PMID:15947480 |
|
NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
multiple interactions affects binding increases activity increases response to substance |
ISO |
[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein; [Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein; alpha-pentyl-3-(2-quinolinylmethoxy)benzenemethanol inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; BAY u9773 inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; BAY u9773 inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; BAY u9773 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; CGP 57698 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]; iralukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein; LY 171883 inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; MEN91507 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; montelukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; montelukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; montelukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pobilukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; pobilukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; pobilukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; pranlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; pranlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; verlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; verlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of CXCL8 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zafirlukast inhibits the reaction [CYSLTR1 protein promotes the reaction [Leukotriene D4 results in increased abundance of Calcium]]; zafirlukast inhibits the reaction [CYSLTR1 protein results in increased susceptibility to Leukotriene D4]; zafirlukast inhibits the reaction [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein] [Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; CYSLTR1 protein binds to and affects the susceptibility to Leukotriene D4; Leukotriene C4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; Leukotriene D4 binds to and results in increased activity of CYSLTR1 protein; Leukotriene E4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein] |
CTD |
PMID:8014876 PMID:8384568 PMID:9620942 PMID:9647482 PMID:10391245 PMID:10462554 PMID:10825389 PMID:11093801 PMID:11705452 PMID:11932261 PMID:11996896 PMID:12853847 PMID:14718577 PMID:15792791 PMID:15990778 PMID:18651869 PMID:18704935 PMID:20083671 More...
|
|
NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Cysltr2 |
cysteinyl leukotriene receptor 2 |
multiple interactions |
ISO |
[Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased chemical synthesis of inositol 1-phosphate; [Leukotriene D4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; BAY u9773 inhibits the reaction [[Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium]; Leukotriene D4 binds to and results in increased activity of CYSLTR2 protein; Leukotriene D4 promotes the reaction [CYSLTR2 protein binds to ARRB1 protein]; Leukotriene D4 promotes the reaction [CYSLTR2 protein binds to ARRB2 protein]; montelukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; pranlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; verlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein]; zafirlukast inhibits the reaction [Leukotriene D4 binds to CYSLTR2 protein] |
CTD |
PMID:10851239 PMID:11093801 PMID:33288675 |
|
NCBI chr15:48,189,476...48,228,750
Ensembl chr15:48,189,073...48,304,136
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
Leukotriene D4 results in decreased expression of FAS protein |
CTD |
PMID:15990778 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity multiple interactions |
ISO |
Leukotriene D4 results in increased activity of GPR17 protein montelukast inhibits the reaction [Leukotriene D4 results in increased activity of GPR17 protein] |
CTD |
PMID:18974869 |
|
NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
Leukotriene D4 promotes the reaction [ICAM1 protein results in increased expression of TGFB1 protein] |
CTD |
PMID:15947480 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Il12a |
interleukin 12A |
multiple interactions |
ISO |
BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:19118273 |
|
NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734
|
|
G |
Il12b |
interleukin 12B |
multiple interactions |
ISO |
BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of [IL12A protein binds to IL12B protein]] |
CTD |
PMID:19118273 |
|
NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903
|
|
G |
Il13 |
interleukin 13 |
increases abundance multiple interactions |
EXP |
IL13 protein results in increased abundance of Leukotriene D4 [IL13 protein results in increased abundance of Leukotriene D4] which results in increased secretion of MUC5AC protein |
CTD |
PMID:12654629 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Il5 |
interleukin 5 |
multiple interactions |
ISO |
Leukotriene D4 promotes the reaction [IL5 protein results in increased expression of TGFB1 protein] |
CTD |
PMID:15947480 |
|
NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases secretion |
ISO |
[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein; BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of IL6 protein]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of IL6 protein] |
CTD |
PMID:18704935 PMID:19118273 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
increases phosphorylation |
ISO |
Leukotriene D4 results in increased phosphorylation of MAPK1 protein |
CTD |
PMID:19837106 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
increases phosphorylation |
ISO |
Leukotriene D4 results in increased phosphorylation of MAPK3 protein |
CTD |
PMID:19837106 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Leukotriene D4 results in decreased activity of MGST1 protein |
CTD |
PMID:9890956 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Mmp9 |
matrix metallopeptidase 9 |
multiple interactions increases expression |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Leukotriene D4 results in increased expression of MMP9 protein]; SB 203580 inhibits the reaction [Leukotriene D4 results in increased expression of MMP9 protein] |
CTD |
PMID:19837106 |
|
NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
multiple interactions increases expression |
EXP |
[IL13 protein results in increased abundance of Leukotriene D4] which results in increased secretion of MUC5AC protein; verlukast inhibits the reaction [Leukotriene D4 results in increased expression of MUC5AC mRNA]; verlukast inhibits the reaction [Leukotriene D4 results in increased expression of MUC5AC protein] Leukotriene D4 results in increased expression of MUC5AC mRNA; Leukotriene D4 results in increased expression of MUC5AC protein |
CTD |
PMID:12654629 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Pdgfrb |
platelet derived growth factor receptor beta |
multiple interactions |
ISO |
6,7-dimethoxy-3-phenylquinoxaline inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein]; bisindolylmaleimide I inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein]; Leukotriene D4 promotes the reaction [SRC protein binds to PDGFRB protein]; Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein; lipoxin A4 inhibits the reaction [Leukotriene D4 results in increased activity of PDGFRB protein]; pobilukast inhibits the reaction [Leukotriene D4 results in increased phosphorylation of and results in increased activity of PDGFRB protein] |
CTD |
PMID:12223454 |
|
NCBI chr18:54,499,962...54,538,840
Ensembl chr18:54,499,964...54,538,843
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased abundance of Leukotriene D4] |
CTD |
PMID:25432964 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
G |
Selp |
selectin P |
increases expression |
ISO |
Leukotriene D4 results in increased expression of SELP protein |
CTD |
PMID:9152370 |
|
NCBI chr13:76,476,229...76,511,846
Ensembl chr13:76,476,295...76,511,845
|
|
G |
Src |
SRC proto-oncogene, non-receptor tyrosine kinase |
multiple interactions |
ISO |
Leukotriene D4 promotes the reaction [SRC protein binds to PDGFRB protein]; Leukotriene D4 results in increased phosphorylation of and results in increased activity of SRC protein; pobilukast inhibits the reaction [Leukotriene D4 results in increased activity of SRC protein] |
CTD |
PMID:12223454 |
|
NCBI chr 3:146,091,969...146,139,492
Ensembl chr 3:146,091,841...146,139,476
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
Leukotriene D4 promotes the reaction [CSF2 protein results in increased expression of TGFB1 protein]; Leukotriene D4 promotes the reaction [ICAM1 protein results in increased expression of TGFB1 protein]; Leukotriene D4 promotes the reaction [IL5 protein results in increased expression of TGFB1 protein] |
CTD |
PMID:15947480 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions increases secretion |
ISO |
[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein; BAY u9773 inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein]; montelukast inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein]; zafirlukast inhibits the reaction [[Leukotriene D4 results in increased activity of CYSLTR1 protein] which results in increased expression of TNF protein]; zileuton inhibits the reaction [Leukotriene D4 results in increased secretion of TNF protein] |
CTD |
PMID:18704935 PMID:19118273 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions |
ISO |
ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]; zileuton inhibits the reaction [ALOX5 protein promotes the reaction [Ovalbumin results in increased abundance of Leukotriene E4]] [zileuton results in decreased activity of ALOX5 protein] which results in decreased abundance of Leukotriene E4 |
CTD |
PMID:8621850 PMID:10764316 PMID:12794006 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
affects binding multiple interactions |
ISO |
Leukotriene E4 binds to CYSLTR1 protein [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] which results in increased abundance of Calcium; Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein; montelukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein]; zafirlukast inhibits the reaction [Leukotriene E4 binds to and results in increased activity of CYSLTR1 protein] Leukotriene E4 inhibits the reaction [Leukotriene D4 binds to CYSLTR1 protein] |
CTD |
PMID:8384568 PMID:9620942 PMID:10462554 PMID:11705452 PMID:12853847 |
|
NCBI chr X:71,661,421...71,690,012
Ensembl chr X:71,663,821...71,690,121
|
|
G |
Cysltr2 |
cysteinyl leukotriene receptor 2 |
multiple interactions increases activity |
ISO |
[Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; [Leukotriene E4 results in increased activity of CYSLTR2 protein] which results in increased abundance of Calcium; Leukotriene E4 binds to and results in increased activity of CYSLTR2 protein |
CTD |
PMID:10851239 PMID:11093801 |
|
NCBI chr15:48,189,476...48,228,750
Ensembl chr15:48,189,073...48,304,136
|
|
G |
Gpr17 |
G protein-coupled receptor 17 |
increases activity |
ISO |
Leukotriene E4 results in increased activity of GPR17 protein |
CTD |
PMID:18974869 |
|
NCBI chr18:23,576,232...23,583,153
Ensembl chr18:23,577,242...23,582,966
|
|
G |
Il13 |
interleukin 13 |
increases abundance |
EXP |
IL13 protein results in increased abundance of Leukotriene E4 |
CTD |
PMID:12654629 |
|
NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737
|
|
G |
Mgst1 |
microsomal glutathione S-transferase 1 |
decreases activity |
EXP |
Leukotriene E4 results in decreased activity of MGST1 protein |
CTD |
PMID:9890956 |
|
NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892
|
|
G |
Muc5ac |
mucin 5AC, oligomeric mucus/gel-forming |
increases expression |
EXP |
Leukotriene E4 results in increased expression of MUC5AC protein |
CTD |
PMID:12654629 |
|
NCBI chr 1:196,864,336...196,896,475
Ensembl chr 1:196,864,336...196,896,475
|
|
G |
Ptgs1 |
prostaglandin-endoperoxide synthase 1 |
multiple interactions |
ISO |
PTGS1 gene mutant form promotes the reaction [Carbon Tetrachloride results in increased abundance of Leukotriene E4] |
CTD |
PMID:25432964 |
|
NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586
|
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 mRNA]; lipoxin A4 inhibits the reaction [Ovalbumin results in increased expression of ACTA2 protein] |
CTD |
PMID:34537180 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Agt |
angiotensinogen |
multiple interactions |
ISO |
2-(1-carboxy-2-(3-(3,5-dichlorobenzyl)-3H-imidazol-4-yl)ethylamino)-4-methylpentanoic acid inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; 7-Ala-angiotensin (1-7) inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; butyloxycarbonyl-phenylalanyl-leucyl-phenylalanyl-leucyl-phenylalanine inhibits the reaction [lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form]]; lipoxin A4 inhibits the reaction [lipopolysaccharide, E coli O55-B5 results in decreased expression of AGT protein alternative form] |
CTD |
PMID:29969931 |
|
NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977
|
|
G |
Ahr |
aryl hydrocarbon receptor |
multiple interactions |
ISO |
AHR affects the reaction [lipoxin A4 results in increased expression of SOCS2 mRNA] |
CTD |
PMID:16415877 |
|
NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568
|
|
G |
Alox5 |
arachidonate 5-lipoxygenase |
multiple interactions affects abundance |
EXP |
zileuton inhibits the reaction [ALOX5 protein affects the abundance of lipoxin A4] |
CTD |
PMID:15326064 |
|
NCBI chr 4:149,531,329...149,578,696
Ensembl chr 4:149,531,515...149,578,743
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [Lipopolysaccharides results in increased expression of BAX protein] |
CTD |
PMID:23063943 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
lipoxin A4 inhibits the reaction [Lipopolysaccharides results in decreased expression of BCL2 protein] |
CTD |
PMID:23063943 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expressi |